<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title>Frontiers in Psychiatry</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Psychiatry</abbrev-journal-title>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpsyt.2017.00272</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Neurological Soft Signs in Schizophrenia: An Update on the State- versus Trait-Perspective</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bachmann</surname> <given-names>Silke</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="corresp" rid="cor1">&#x0002A;</xref>
<uri xlink:href="http://frontiersin.org/people/u/192449"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Schr&#x000F6;der</surname> <given-names>Johannes</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="http://frontiersin.org/people/u/143542"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Psychiatry, Psychotherapy, and Psychosomatics, University Hospitals of Halle (Saale)</institution>, <addr-line>Halle</addr-line>, <country>Germany</country></aff>
<aff id="aff2"><sup>2</sup><institution>Clienia Littenheid AG, Hospital for Psychiatry and Psychotherapy</institution>, <addr-line>Littenheid</addr-line>, <country>Switzerland</country></aff>
<aff id="aff3"><sup>3</sup><institution>Section of Geriatric Psychiatry, Department of General Psychiatry, Center for Psychosocial Medicine, University of Heidelberg</institution>, <addr-line>Heidelberg</addr-line>, <country>Germany</country></aff>
<author-notes>
<fn fn-type="edited-by"><p>Edited by: Philip D. Harvey, Leonard M. Miller School of Medicine, United States</p></fn>
<fn fn-type="edited-by"><p>Reviewed by: Assen Veniaminov Jablensky, University of Western Australia, Australia; Roberto Cavallaro, Vita-Salute San Raffaele University, Italy</p></fn>
<corresp content-type="corresp" id="cor1">&#x0002A;Correspondence: Silke Bachmann, <email>silke.bachmann&#x00040;clienia.ch</email></corresp>
<fn fn-type="other" id="fn001"><p>Specialty section: This article was submitted to Schizophrenia, a section of the journal Frontiers in Psychiatry</p></fn>
</author-notes>
<pub-date pub-type="epub">
<day>08</day>
<month>01</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<year>2017</year>
</pub-date>
<volume>8</volume>
<elocation-id>272</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>09</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>11</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2018 Bachmann and Schr&#x000F6;der.</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>Bachmann and Schr&#x000F6;der</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p></license>
</permissions>
<abstract abstract-type="executive-summary">
<sec id="ST1">
<title>Background</title>
<p>Neurological soft signs (NSS) represent minor neurological signs, which indicate non-specific cerebral dysfunction. In schizophrenia, their presence has been documented extensively across all stages of the disease. Until recently, NSS were considered an endophenotype or a trait phenomenon. During the past years, however, researchers report fluctuations of the NSS scores.</p>
</sec>
<sec id="ST2">
<title>Aims</title>
<p>To further clarify the question whether NSS exhibit state or trait components or both, studies that have investigated NSS longitudinally were reviewed.</p>
</sec>
<sec id="ST3">
<title>Method</title>
<p>Studies which have assessed NSS longitudinally in adults suffering from schizophrenia, were searched for. The time frame was January 1966 to June 2017. Studies on teenagers were excluded because of interferences between brain maturation and pathology.</p>
</sec>
<sec id="ST4">
<title>Results</title>
<p>Twenty-nine follow-up studies were identified. They included patients during different stages of their illness and mainly used established instruments for NSS assessment. Patients with a first episode or a remitting course predominantly show a decrease of NSS over time, whereas a worsening of NSS can be found in the chronically ill. It was shown that change of NSS total scores over time is predominantly caused by motor system subscales and to a lesser extent by sensory integration scales. With respect to medication, the majority of studies agree on a relationship between medication response and improvement of NSS while the type of antipsychotic does not seem to play a major role. Moreover, where information on side-effects is given, it does not favor a strong relationship with NSS. However, NSS seem to correlate with negative and cognitive symptoms.</p>
</sec>
<sec id="ST5">
<title>Conclusion</title>
<p>Studies manifest a conformity regarding the presence of NSS in schizophrenia patients on the one hand. On the other hand, fluctuations of NSS scores have been widely described in subgroups. Taken together results strongly support a state-trait dichotomy of NSS. Thus, the usage of NSS as an endophenotype has to be called into question.</p>
</sec>
</abstract>
<kwd-group>
<kwd>schizophrenia</kwd>
<kwd>neurological soft signs</kwd>
<kwd>longitudinal</kwd>
<kwd>follow-up</kwd>
<kwd>state</kwd>
<kwd>trait</kwd>
<kwd>review</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="2"/>
<equation-count count="0"/>
<ref-count count="107"/>
<page-count count="16"/>
<word-count count="11492"/>
</counts>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="introduction">
<title>Introduction</title>
<p>It is generally accepted that neurological soft signs (NSS) are present in schizophrenia patients. These neurological abnormalities do not reflect hard pathology, i.e., localized, nuclear, or primary tract lesions (<xref ref-type="bibr" rid="B1">1</xref>&#x02013;<xref ref-type="bibr" rid="B3">3</xref>) and are, therefore, labeled &#x0201C;soft.&#x0201D; Overall, in schizophrenia patients, distinctive NSS consistently pertain to motor coordination, motor sequencing, and sensory integration [review by Boks et al. (<xref ref-type="bibr" rid="B4">4</xref>)], but also to eye movements and developmental reflexes (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B5">5</xref>). In first-episode (FE) patients NSS mostly strike motor coordination, motor sequencing, and developmental reflexes [review by Dazzan and Murray (<xref ref-type="bibr" rid="B6">6</xref>)].</p>
<p>Yet, the presence of NSS is not specific to schizophrenia. In early studies, they were detected in 5% (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>) to 50% (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>) of healthy individuals, depending on the instrument used. NSS can be found in patients with mood disorders (<xref ref-type="bibr" rid="B11">11</xref>), obsessive&#x02013;compulsive disorder (<xref ref-type="bibr" rid="B12">12</xref>), and personality disorders (<xref ref-type="bibr" rid="B13">13</xref>). However, the incidence of NSS is higher in schizophrenia compared to other psychiatric disorders [review by Dazzan and Murray (<xref ref-type="bibr" rid="B6">6</xref>)].</p>
<p>Also, compared to healthy controls (HC) NSS occurrence in schizophrenia patients is more pronounced with regard to both quantity and quality (<xref ref-type="bibr" rid="B14">14</xref>). Several reviews have summarized the respective research results on schizophrenia patients (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B15">15</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>). These reviews also emphasize that NSS and abnormal movements similar to tardive dyskinesia are not sequelae of neuroleptic medication but an integral part of the disease as has been described by Kraepelin for the first time in the end of the nineteenth century (<xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>Predominantly, NSS have been looked at as endophenotypes, i.e., hardcopies of the genetic liability and thus as a trait phenomenon. In fact, much support for this notion derives from the literature on neuroleptic-na&#x000EF;ve patients. The review by Wolff and O&#x02019;Driscoll (<xref ref-type="bibr" rid="B20">20</xref>) reports a rate of approximately 25&#x02013;33% NSS in this group and elevated rates in high-risk subjects with an emphasis on motor abnormalities.</p>
<p>Another strong piece of evidence supporting the trait aspect of NSS stems from FE studies [review by Dazzan and Murray (<xref ref-type="bibr" rid="B6">6</xref>)], where the reported prevalence ranges from 20 to 97% of patients. In contrast, NSS can be ascertained in up to 60% of patients treated with antipsychotic medication compared to less than 1% in healthy subjects (<xref ref-type="bibr" rid="B14">14</xref>). Yet another argument underpinning the trait hypothesis is provided by the literature on increased NSS in first-degree relatives (<xref ref-type="bibr" rid="B20">20</xref>) and more specifically by twin studies (<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B24">24</xref>) as well as by studies on patients&#x02019; off-spring, i.e., high-risk individuals (<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>). Interestingly, NSS abnormalities are comparable in patients and their relatives, they affect motor coordination, motor sequencing, and sensory integration.</p>
<p>On the whole, the literature thus offers good evidence in favor of NSS representing a trait phenomenon which again is in line with the neurodevelopmental hypothesis (<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>Despite the aforementioned evidence, a number of studies present arguments in favor of a state feature being present in NSS. First and foremost, follow-up studies report clearly marked fluctuations regarding the expression of NSS during the disease course (<xref ref-type="bibr" rid="B29">29</xref>&#x02013;<xref ref-type="bibr" rid="B31">31</xref>). These fluctuations concern quality more than quantity (number) of abnormal NSS. Thus, single NSS may reach a higher level during acute phases of the disease and return to a baseline thereafter. However, this baseline does not compare to healthy individuals but rather to healthy first-degree relatives (<xref ref-type="bibr" rid="B22">22</xref>).</p>
<p>The documentation of a NSS state component may bear the following impact:
<list list-type="order">
<list-item><p>it may argue in favor of the existence of neuronal regeneration processes in individuals suffering from schizophrenia.</p></list-item>
<list-item><p>it may represent an argument for the necessity to supplement the neurodevelopmental hypothesis.</p></list-item>
<list-item><p>it may&#x02014;together with fluctuations in symptomatology&#x02014;hint at a third underlying factor influencing the disease process.</p></list-item>
</list></p>
<p>This paper aims to raise the question whether NSS are constituted by trait properties only or whether there is another property, namely state component, or whether NSS are even Janus-faced. This state-trait discussion can only be led with reference to follow-up studies.</p>
<p>Moreover, this paper represents an update on our meta-analysis (<xref ref-type="bibr" rid="B32">32</xref>), where only studies were incorporated which gave sufficient statistical data, so that several meaningful longitudinal studies were not included.</p>
</sec>
<sec id="S2" sec-type="methods">
<title>Methods</title>
<p>We performed a literature search of the period between January 1966 and June 2017 in the following databases: PsycNET, PSycINFO, Psyndex, and SCOPUS which includes PubMed. We used the following terms: schizophren&#x0002A; AND neurology&#x0002A; OR soft sign OR motor AND follow-up OR longitudinal OR Verlauf (German word for course, used in the German database Psyndex only). In addition, we examined references from all articles identified. Moreover, we excluded literature on children and adolescents because NSS are present at birth and decrease over time at least until puberty. They are, thus, correlated with brain maturation (<xref ref-type="bibr" rid="B33">33</xref>), reaching a &#x0201C;normal&#x0201D; level only in early adulthood.</p>
</sec>
<sec id="S3" sec-type="discussion">
<title>Discussion</title>
<sec id="S3-1">
<title>Patients, Instruments, Follow-up Period</title>
<p>We identified 26 studies (see Table <xref ref-type="table" rid="T1">1</xref>) which had performed follow-up assessments of patients diagnosed with schizophrenia or related disorders. These studies were presented by 18 groups, 3 of which (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B37">37</xref>&#x02013;<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B41">41</xref>&#x02013;<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>) had carried out two to five studies each. Two other groups published two to three papers each on different follow-up examinations of one patient samples (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B58">58</xref>). Therefore, the latter data were merged for this review&#x02019;s purpose.</p>
<table-wrap position="float" id="T1">
<label>Table 1</label>
<caption><p>Longitudinal studies on patients with schizophrenia in alphabetical order.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Reference</th>
<th valign="top" align="left">Subjects gender handedness controls</th>
<th valign="top" align="left">Age</th>
<th valign="top" align="center">Follow-up (weeks)</th>
<th valign="top" align="left">Instruments</th>
<th valign="top" align="left">First NSS assessment</th>
<th valign="top" align="left">Medication</th>
<th valign="top" align="left">Clinical course</th>
<th valign="top" align="left">Side-effects (SE)</th>
<th valign="top" align="left">NSS</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">Bachmann et al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td align="left" valign="top">39 first-episode (FE)<break/>18&#x02009;m, 21 f</td>
<td align="left" valign="top">27 (7.7)</td>
<td align="center" valign="top">60 (6.4)</td>
<td align="left" valign="top">HD<break/>2 raters<break/>IRR 0.88</td>
<td align="left" valign="top">Following clinical stabilization</td>
<td align="left" valign="top">Atypicals</td>
<td align="left" valign="top">PANSS<break/>t0: 52.4 (25.6)<break/>t1: 52.0 (12.4)</td>
<td align="left" valign="top">AIMS<break/>Barnes<break/>SARS</td>
<td align="left" valign="top">t0: 15.7 (7.1)<break/>t1: 10.1 (7.9)<break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001</td>
</tr>
<tr>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top">handedness: 20 r, 19 mixed</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">21&#x02009;R<break/>18 NR</td>
<td align="left" valign="top">no SE</td>
<td align="left" valign="top">R<break/>t0: 17.3 (6.8)<break/>t1: 7.2 (5.8)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">22 healthy controls (HC)</td>
<td align="left" valign="top">28 (3.8)</td>
<td align="center" valign="top">40 (5.6)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">NR<break/>t0: 13.8 (7.2)<break/>t1: 13.5 (8.7)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Beher (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td align="left" valign="top">17 FE<break/>9&#x02009;m, 8 f</td>
<td align="left" valign="top">32.7 (7.2)</td>
<td align="center" valign="top">321 (104)</td>
<td align="left" valign="top">NES modified<break/>1 rater</td>
<td align="left" valign="top">Antipsychotic na&#x000EF;ve</td>
<td align="left" valign="top">&#x0201C;Antipsychotics&#x0201D;</td>
<td align="left" valign="top">Positive<break/>24.9 (5.5)<break/>14.1 (9.4)<break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001</td>
<td align="left" valign="top">AIMS SARS</td>
<td align="left" valign="top">Motor coordination<break/>t0: 2.0 (2.1)<break/>t1: 1.9 (2.1)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Negative<break/>18.3 (8.6)<break/>18.0 (7.7)</td>
<td align="left" valign="top">no SE</td>
<td align="left" valign="top">Sequential movement<break/>t0: 4.4 (3.1)<break/>t1: 4.1 (2.8)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">General<break/>38.5 (8.8)<break/>31.6 (8.7<italic>)</italic><break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Sensory integration<break/>t0: 4.3 (3.4)<break/>t1: 2.3 (2.2)</td>
</tr>
<tr>
<td align="left" valign="top">India</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Primitive reflexes<break/>t0: 2.8 (2.4)<break/>t1: 1.6 (1.5)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Boks et al. (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td align="left" valign="top">29 FE</td>
<td align="left" valign="top">26.9 (6.3)</td>
<td align="center" valign="top">104&#x02009;(<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>2 raters<break/>ICC 0.66</td>
<td align="left" valign="top">&#x0201C;After first episode&#x0201D;</td>
<td align="left" valign="top">15 atypicals<break/>11 typicals<break/>3 none</td>
<td align="left" valign="top">t0: 57.0 (17.4)<break/>t1: 52.9 (15.6)</td>
<td align="left" valign="top">n.d.</td>
<td align="left" valign="top">t0: 7.5 (7.1)<break/>t1: 8.9 (5.5)</td>
</tr>
<tr>
<td align="left" valign="top">The Netherlands</td>
<td align="left" valign="top">18&#x02009;m, 11 f<break/>handedness<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">3 groups:<break/>Increased<break/>Unchanged<break/>Decreased</td>
<td align="left" valign="top"/>
<td align="left" valign="top">n.s.</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Buchanan et al. (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td align="left" valign="top">31 CH<break/>21&#x02009;m, 10 f</td>
<td align="left" valign="top">34.1 (6.8)<break/>34.6 (9.1)</td>
<td align="center" valign="top">10&#x02009;(<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>10&#x02009;(<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>2 raters<break/>IRR 0.81&#x02013;0.98</td>
<td align="left" valign="top">After 6&#x02009;weeks fluphenazine, prior to double blind phase</td>
<td align="left" valign="top">16 clozapine<break/>15 haloperidole (double blind)</td>
<td align="left" valign="top">t0: 11.4 (5.8)<break/>t1: 9.4 (5.2)</td>
<td align="left" valign="top">SARS TD</td>
<td align="left" valign="top">t0: 16.2 (5.9)<break/>t1: 16.8 (8.2)</td>
</tr>
<tr>
<td align="left" valign="top">USA</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">t0: 12.6 (5.3)<break/>t1: 12.0 (5.1)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">t0: 14.5 (6.3)<break/>t1: 15.1 (7.5)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Chan et al. (<xref ref-type="bibr" rid="B37">37</xref>)</td>
<td align="left" valign="top">109 FE<break/>69&#x02009;m, 78 f at t0</td>
<td align="left" valign="top">Neg. sym. 22.3 (4.1)</td>
<td align="center" valign="top">26 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">CNI<break/>3 raters<break/>ICC 0.85&#x02013;0.91</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">About 90% atypicals</td>
<td align="left" valign="top">Negative symptoms<break/>60.9 (13.9)</td>
<td align="left" valign="top">AIMS<break/>Barnes<break/>SARS</td>
<td align="left" valign="top">Negative symptoms<break/>7.1 (3.2)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">No negative symptoms<break/>5.6 (3.1)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Handedness: 137 r, 8&#x02009;l at t0</td>
<td align="left" valign="top">No neg. sym.<break/>21.7 (3.8)</td>
<td align="center" valign="top">52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">PANSS<break/>DSM-IV<break/>Logical Memory</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">No negative symptoms<break/>42.2 (14.9)</td>
<td align="left" valign="top">Unchanged</td>
<td align="left" valign="top">HC 2.8 (2.2)</td>
</tr>
<tr>
<td align="left" valign="top">China</td>
<td align="left" valign="top">62 HC<break/>32&#x02009;m, 30 f<break/>60 r, 2&#x02009;l</td>
<td align="left" valign="top">21.2 (1.9)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Visual Reproduction<break/>Letter-Number Span Test<break/>Verbal fluency<break/>WCST</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Motor Coordination<break/>3.68 (1.98)<break/>2.64 (1.88)<break/>&#x0003C;0.001<break/>1.34 (1.28)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Sensory Integration<break/>2.26 (1.50)<break/>1.99 (1.40)<break/>&#x0003C;0.001<break/>0.74 (1.13)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Disinhibition<break/>1.19 (0.97)<break/>0.98 (0.93)<break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05<break/>0.68 (0.65)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Chen et al. (38)</td>
<td align="left" valign="top">43 CH<break/>30&#x02009;m, 13 f</td>
<td align="left" valign="top">48.9 (8.9)</td>
<td align="center" valign="top">152 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">CNI<break/>2 raters<break/>ICC 0.45&#x02013;0.95</td>
<td align="left" valign="top">Chronic</td>
<td align="left" valign="top">Typicals</td>
<td align="left" valign="top">t1: 27.6 (6.7)<break/>t2: 28.3 (5.9)</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">Motor Coordination<break/>t0: 17.5 (21.1)<break/>t1: 26.0 (24.8)</td>
</tr>
<tr>
<td align="left" valign="top">China</td>
<td align="left" valign="top">40 HC</td>
<td align="left" valign="top">48.4 (8.4)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Sensory Integration<break/>t0: 14.4 (16.5)<break/>t1: 25.4 (22.7)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Disinhibition<break/>t0: 11.4 (11.8)<break/>t1: 24.5 (19.0)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Chen et al. (39)</td>
<td align="left" valign="top">93 FE<break/>42&#x02009;m, 51 f</td>
<td align="left" valign="top">31.2 (9.6)</td>
<td align="center" valign="top">6 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>104 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>156 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">CNI<break/>2 raters<break/>ICC 0.93</td>
<td align="left" valign="top">Acute phase</td>
<td align="left" valign="top">48 antipsychotic na&#x000EF;ve<break/>45 max. 7 d low dose haloperidol</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">AIMS<break/>Barnes<break/>SARS</td>
<td align="left" valign="top">t0: 1.87 (2)<break/>t4: 1.45 (2.2)</td>
</tr>
<tr>
<td align="left" valign="top">China</td>
<td align="left" valign="top">68 HC</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Unchanged</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Cuesta et al. (40)</td>
<td align="left" valign="top">77 FE<break/>53&#x02009;m, 24 f</td>
<td align="left" valign="top">30.1 (10)<break/>30.6 (6.2)</td>
<td align="center" valign="top">t1: 4(<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>t2: 26 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>2 raters<break/>ICC 0.71&#x02013;0.99</td>
<td align="left" valign="top">Acute<break/>Antipsychotic na&#x000EF;ve</td>
<td align="left" valign="top">Risperidone<break/>Olanzapine<break/>Both<break/>None</td>
<td align="left" valign="top">SAPS<break/>t0: 10.1 (3.5)<break/>t2: 1.6 (2.1)</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref> 31% clinically meaningful change</td>
<td align="left" valign="top">t0: 17.1 (9.4)<break/>t1: 12.0 (7.9)<break/>t2: 9.9 (6.8)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">SAPS</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">SANS</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Spain</td>
<td align="left" valign="top">28 HC<break/>19&#x02009;m, 9 f</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">SANS<break/>DSM-IV</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">t0: 8.0(5.9)<break/>t2: 4.7(4.9)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Emsley et al. (41)</td>
<td align="left" valign="top">66 FE<break/>m 31, f 35</td>
<td align="left" valign="top">28.1 (8.5)</td>
<td align="center" valign="top">t1: 13(<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>t2: 26 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>t3: 52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES: 13 items<break/>1 rater</td>
<td align="left" valign="top">60 antipsychotic na&#x000EF;ve</td>
<td align="left" valign="top">&#x0201C;very low doses of haloperidol&#x0201D;</td>
<td align="left" valign="top">t0: 92.1 (16.2)t1-t3:<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">AIMS<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref><break/>Barnes<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref><break/>SARS<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">t0: 6.7 (3.7)<break/>t1-t3:<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top">South Africa</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV<break/>Cognition</td>
<td align="left" valign="top">6 max. of 4&#x02009;weeks of antipsychotic medication</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">&#x0201C;no significant change over time&#x0201D;</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Emsley et al. (<xref ref-type="bibr" rid="B42">42</xref>)</td>
<td align="left" valign="top">126 FE<break/>93&#x02009;m, 33 f</td>
<td align="left" valign="top">24.1 (6.6)</td>
<td align="center" valign="top">t1: 26 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>t2: 52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES: 13 items<break/>3 raters<break/>IRR &#x0003E;0.9</td>
<td align="left" valign="top">Max. 4&#x02009;weeks of antipsychotic medication</td>
<td align="left" valign="top">Flupenthixol p.o. followed by i.m.</td>
<td align="center" valign="top">94.8 (16.5)<break/>52.9 (17.9)<break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.0001</td>
<td align="left" valign="top">ESRS<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="center" valign="top">15.02 (7.99)<break/>10.72 (6.71)<break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.0001</td>
</tr>
<tr>
<td align="left" valign="top">South Africa</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV<break/>MATRICS<break/>MCCB</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Jahn et al. (<xref ref-type="bibr" rid="B43">43</xref>)</td>
<td align="left" valign="top">82 (18&#x02013;50)<break/>CH 28<break/>R 26<break/>FE 22, unclear 6</td>
<td align="center" valign="top">29.6 (7.0)</td>
<td align="left" valign="top">t1: 2(<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">BMS<break/>1 rater</td>
<td align="left" valign="top">Subacute phase of illness</td>
<td align="left" valign="top">42 typicals<break/>33 CLZ<break/>3 CLZ and typical<break/>3 none</td>
<td align="center" valign="top">39.0 (24&#x02013;87)</td>
<td align="left" valign="top">AIMS<break/>Barnes<break/>SARS</td>
<td align="center" valign="top">5.50 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top">m 55, f 27</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R<break/>WCST modified</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Correlation of SARS and motor signs</td>
<td align="left" valign="top">Improving or stable patients: significant decrease in motor signs</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>)</td>
<td align="left" valign="top">18 FE<break/>11&#x02009;m, 7 f</td>
<td align="left" valign="top">28.5 (20&#x02013;41)</td>
<td align="center" valign="top">260 (5 years)</td>
<td align="left" valign="top">Extended standard neurological examination</td>
<td align="left" valign="top">At first admission</td>
<td align="left" valign="top">13 &#x0201C;antipsychotics&#x0201D;</td>
<td align="left" valign="top">SANS<break/>t0: 6.0 (0&#x02013;11)<break/>t1: 3.0 (0&#x02013;9)</td>
<td align="left" valign="top">Hans rating scale<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">Deterioration in male patients, in patients with OC, with genetic load, without remission</td>
</tr>
<tr>
<td align="left" valign="top">Denmark</td>
<td align="left" valign="top">10 HC<break/>5 m, 5 f</td>
<td align="left" valign="top">28 (23&#x02013;38)</td>
<td align="left" valign="top">1 rater<break/>PSE-9<break/>SANS, SAPS<break/>ICD-10</td>
<td align="left" valign="top"/>
<td align="left" valign="top">5 none</td>
<td align="left" valign="top">SAPS<break/>t0: 6.5 (2&#x02013;14)<break/>t1: 5.5 (1&#x02013;22)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Mangot and Sawant (<xref ref-type="bibr" rid="B45">45</xref>)<break/><break/>India</td>
<td align="left" valign="top">40 FE<break/>21&#x02009;m, 19 f</td>
<td align="left" valign="top">35.5 (11.9)</td>
<td align="center" valign="top">24 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>) 52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>1 rater<break/>PANSS<break/>ICD-10</td>
<td align="left" valign="top">At first admission<break/>Antipsychotic na&#x000EF;ve</td>
<td align="left" valign="top">Risperidone</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"/>
<td align="left" valign="top">t0: 8.5 (7.1)<break/>t1: 5.5 (5.8) <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.001<break/>t2: 3.3 (4.1)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Mittal et al. (<xref ref-type="bibr" rid="B46">46</xref>)</td>
<td align="left" valign="top">19 CH<break/>19&#x02009;m</td>
<td align="center" valign="top">36.3 (5.4)</td>
<td align="center" valign="top">6 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">Quitkin scale<break/>1 rater</td>
<td align="left" valign="top">Min. 6&#x02009;weeks off medication</td>
<td align="left" valign="top">Haloperidol</td>
<td align="left" valign="top">t0: 34.3 (2.1)<break/>t1: 22.4 (2.2)</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">t0: 6.3 (0.9)<break/>t1: 5.3 (0.8)</td>
</tr>
<tr>
<td align="left" valign="top">USA</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R</td>
<td align="left" valign="top">min. BPRS score 30</td>
<td align="left" valign="top"/>
<td align="left" valign="top"><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.01</td>
<td align="left" valign="top"/>
<td align="left" valign="top"><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Ojagbemi et al. (<xref ref-type="bibr" rid="B47">47</xref>)<break/><break/>Nigeria</td>
<td align="left" valign="top">66 FE<break/>36&#x02009;m, 30 f</td>
<td align="left" valign="top">28.7 (6.4)</td>
<td align="center" valign="top">t1: 26 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>t2: 52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>1 rater<break/>PANSS<break/>DSM-IV</td>
<td align="left" valign="top">Antipsychotic na&#x000EF;ve except for 5 patient</td>
<td align="left" valign="top">Flupenthixol dec./i.m.</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">ESRS</td>
<td align="left" valign="top">t0: 21.5 (11.1)<break/>t1<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Prikryl et al&#x02009;(<xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>)</td>
<td align="left" valign="top">92 FE<break/>all m</td>
<td align="left" valign="top">23.1 (5.7)</td>
<td align="center" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref><break/>52 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>1 rater</td>
<td align="left" valign="top">Acute</td>
<td align="left" valign="top">Atypicals in 69%</td>
<td align="left" valign="top">All<break/>t0: 97.4 (22.0)<break/>t1: 58.4 (15.3)<break/>t2: 51.5 (19.0)</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">All<break/>t2: 6.79 (6.58)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">68 of this sample at 4&#x02009;years follow-up</td>
<td align="left" valign="top"/>
<td align="center" valign="top">208 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">PANSS<break/>ICD-10</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">72&#x02009;R<break/>t0: 97.6 (22.5)<break/>t1: 57.9 (14.4)<break/>t2: 43.8 (11.1)</td>
<td align="left" valign="top">72&#x02009;R<break/>t0: 5.3 (5.9)<break/>t1: 2.7 (3.4);<break/>p&#x02009;&#x0003C;&#x02009;0.01<break/>t2: 4.4 (4.5)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">20 NR<break/>t0: 6.5 (4.1)<break/>t1: 4.2 (4.1);<break/><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05<break/>t2: 10.1 (7.6)</td>
</tr>
<tr>
<td align="left" valign="top">Czech Republik</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">20 NR<break/>t0: 88.4 (19.9)<break/>t1: 53.0 (14.9)<break/>t2: 84.7 (21.6)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">t0/t1/t2:non-rem&#x02009;&#x0003E;&#x02009;rem; <italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05/&#x02009;&#x0003C;&#x02009;0.005</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Scheffer (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left" valign="top">18 FE<break/>21&#x02009;m, 8 f</td>
<td align="left" valign="top">22.8 (4.2)</td>
<td align="center" valign="top">6 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES<break/>2 raters<break/>ICC &#x0003E;0.80</td>
<td align="left" valign="top">Acute</td>
<td align="left" valign="top">Typicals</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">ESRS<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">t0: 12.1 (5.3)<break/>t1: 13.2 (6.6)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">16 antipsychotic na&#x000EF;ve</td>
<td align="left" valign="top">Clinical needs</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">USA</td>
<td align="left" valign="top">50 HC</td>
<td align="left" valign="top">21.7 (4.0)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" valign="top">50 SCZ:<break/>27 CH<break/>23&#x02009;R<break/>m:f<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">36 (12.1)<break/>28.9 (8.9)</td>
<td align="center" valign="top">t1: remission (variable)</td>
<td align="left" valign="top">HD<break/>2 raters<break/>IRR 0.85</td>
<td align="left" valign="top">Acute</td>
<td align="left" valign="top">17 drug-na&#x000EF;ve</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">SARS</td>
<td align="left" valign="top">t0:<break/>CH 27.8 (9.2)<break/>R 23.5 (8.3)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">clinical needs:<break/>29 typicals<break/>21 clozapine</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Uncorrelated</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top">34 HC</td>
<td align="center" valign="top">25.7 (3.18)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">t1:<break/>CH 22.1 (7.1)<break/>R 13.0 (4.7)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" valign="top">32 CH and R</td>
<td align="center" valign="top">32 (9)</td>
<td align="left" valign="top">Variable</td>
<td align="left" valign="top">HD<break/>2 raters<break/>IRR 0.85</td>
<td align="left" valign="top">Acute</td>
<td align="left" valign="top">Clinical needs</td>
<td align="left" valign="top">t0: 46.1 (7.3)<break/>t1: 32.1 (5.7)</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">t0: 21.3 (8.3)<break/>t1: 11.5 (5.7)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>HC</td>
<td align="center" valign="top">27 (2)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.005</td>
</tr>
<tr>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III<break/>SKT<break/>Tower of Toronto WCST</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B53">53</xref>)</td>
<td align="left" valign="top">15 FE<break/>7 NR<break/>8&#x02009;R</td>
<td align="left" valign="top">29.2 (9.4)</td>
<td align="center" valign="top">4 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">HD<break/>2 raters<break/>IRR 0.85</td>
<td align="left" valign="top">Acute</td>
<td align="left" valign="top">Benperidol</td>
<td align="left" valign="top">All<break/>t0: 48.1 (6.6)<break/>t1: 35.7 (7.7)</td>
<td align="left" valign="top">SARS<break/><break/>Unchanged</td>
<td align="left" valign="top">all<break/>t0: 16.2 (7.5)<break/>t1: 10.0 (4.7)</td>
</tr>
<tr>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">R<break/>t0: 49.4 (7.8)<break/>t1: 32.5 (7.2)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">R<break/>t0: 15.5 (7.2)<break/>t1: 9.3 (4.6)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">NR<break/>t0: 46.7 (5.2)<break/>t1: 39.3 (7.4)</td>
<td align="left" valign="top"/>
<td align="left" valign="top">NR<break/>t0: 17.0 (8.5)<break/>t1: 10.9 (5.0)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Sevincok and Topaloglu (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" valign="top">10&#x02009;R<break/>7&#x02009;m, 3 f</td>
<td align="left" valign="top">24.5 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="center" valign="top">8</td>
<td align="left" valign="top">NES<break/>PANSS<break/>DSM-IV</td>
<td align="left" valign="top">After 2&#x02009;weeks of washout</td>
<td align="left" valign="top">Olanzapine</td>
<td align="left" valign="top">t0: 78.8&#x02009;&#x000B1;&#x02009;19.9<break/>t1: 58.0&#x02009;&#x000B1;&#x02009;13.1</td>
<td align="left" valign="top">AIMS<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref><break/>SARS<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">t0: 19.1 (13.2)<break/>t1: 14.7 (12.5)</td>
</tr>
<tr>
<td align="left" valign="top">Turkey</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05</td>
<td align="left" valign="top"/>
<td align="left" valign="top">n.s.</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Smith et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" valign="top">37 CH<break/>25&#x02009;m, 12 f</td>
<td align="left" valign="top">42.8 (7.6)</td>
<td align="center" valign="top">88.7 (74.3)</td>
<td align="left" valign="top">NES slightly modified<break/>1 or 2 or more raters<break/>ICC 0.82&#x02013;0.99</td>
<td align="left" valign="top">Hospitalized for &#x0003E;1&#x02009;year</td>
<td align="left" valign="top">Typicals</td>
<td align="left" valign="top">t0: 41.9&#x02009;&#x000B1;&#x02009;9.6<break/>t1:<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">t0: 27.1 (11.2)<break/>t1:<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>; n.s.</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">22 pats changed to atypicals</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">62&#x02013;67% stable scores no effect of medication</td>
</tr>
<tr>
<td align="left" valign="top">USA</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">BPRS<break/>DSM-III-R</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">22/37 pats changed to atypicals<break/><break/>t0: 35.35 (9.0)<break/>t1: 32.55 (11.52)</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Tucker and Silberfarb (<xref ref-type="bibr" rid="B1">1</xref>)</td>
<td align="left" valign="top">18<break/>CH or R</td>
<td align="left" valign="top">33.1 (2.0)</td>
<td align="center" valign="top">156 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">4 tests, 1 rater:</td>
<td align="left" valign="top">On hospital admission</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">Impairment</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">finger agnosia, finger-tip number writing, form recognition, tactile performance</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">t1: 61.11% pats<break/>t2: 44.44% pats</td>
</tr>
<tr>
<td align="left" valign="top">USA</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">NHSI and SFRSS</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">&#x0201C;Marked improvement over time&#x0201D;</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Torrey (<xref ref-type="bibr" rid="B56">56</xref>)</td>
<td align="left" valign="top">30 CH and R</td>
<td align="left" valign="top">(In their mid 30ies)</td>
<td align="center" valign="top">52 (4&#x02013;82)</td>
<td align="left" valign="top">2 tests, 1 rater</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">Predominantly fluphenazine</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"/>
<td align="left" valign="top">6 pts improved<break/>4 pts worsened</td>
</tr>
<tr>
<td align="left" valign="top">USA</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">Graphethesia, face-hand test</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">20 pts stable</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Wahlheim et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" valign="top">75&#x02009;R<break/>51 m, 24 f</td>
<td align="center" valign="top">27.3 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="center" valign="top">104 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">From NES: motor sequencing and coordination<break/>1 rater</td>
<td align="left" valign="top">Mostly remitted</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref></td>
<td align="left" valign="top">AIMS<break/>SARS</td>
<td align="left" valign="top">t1: 6.59 (5.36)<break/>t2: 5.49 (5.50)</td>
</tr>
<tr>
<td align="left" valign="top">Germany</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>SANS<break/>DSM-III-R</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top"><italic>p</italic>&#x02009;&#x0003C;&#x02009;0.05</td>
</tr>
<tr>
<td align="left" valign="top" colspan="10"><hr/></td>
</tr>
<tr>
<td align="left" valign="top">Whitty et al. (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B46">46</xref>)</td>
<td align="left" valign="top">73 FE<break/>103 FE:<break/>66 SCZ 37 others</td>
<td align="center" valign="top">23.4 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)28.3 (11.4)</td>
<td align="center" valign="top">26 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)<break/>208 (<xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref>)</td>
<td align="left" valign="top">NES and CNE<break/>1. rater<break/>CNE<break/>2. raters<break/>ICC 0.82</td>
<td align="left" valign="top">Max. 30 days of medication</td>
<td align="left" valign="top">Clinical needs</td>
<td align="left" valign="top">t0: 83.8 (20.1)<break/>t1: 58.4 (15.1)<break/><italic>p</italic> &#x0003C;.001<break/><break/><break/>t2 &#x0002A;</td>
<td align="left" valign="top"><xref ref-type="table-fn" rid="tfn1"><sup>a</sup></xref><break/>NSS<break/>Improvement after 4 years in SCZ pts <italic>p</italic>&#x0003C;0.001</td>
<td align="left" valign="top">NES <italic>p</italic>&#x0003C;.01<break/>t0: 15.6 (9.7)<break/>t1: 12.5 (7.3)<break/><break/>CNE n.s.<break/>t0: 8.6 (6.5)<break/>t1: 7.3 (4.2)</td>
</tr>
<tr>
<td align="left" valign="top">Ireland</td>
<td align="left" valign="top">64 m, 39 f<break/>89 lateralized, 14 mixed-handed</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">PANSS<break/>DSM-IV</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
<td align="left" valign="top">CNI corr NSS<break/><italic>p</italic>&#x0003C;0.0001</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>Authors who published more than one paper on the same group of patients, i.e., at different catamnestic points, are summarized</italic>.</p>
<fn id="tfn1"><p><italic><sup>a</sup>Information not provided</italic>.</p></fn>
<p><italic>Numbers in parenthesis: SD, if one number; range, if two numbers</italic>.</p>
<p><italic>AIMS, Abnormal Involuntary Movement Scale; Barnes, Barnes Rating Scale for Drug-Induced Akathisia; BMS, Brief Motor Scale (<xref ref-type="bibr" rid="B59">59</xref>); BPRS, Brief Psychiatric Rating Scale; CH, Chronic schizophrenia patients; CNE, Condensed Neurological Examination (<xref ref-type="bibr" rid="B60">60</xref>); CNI, Cambridge Neurological Inventory (<xref ref-type="bibr" rid="B61">61</xref>); ESRS, Extrapyramidal Symptom Rating Scale; f, female; FE, first episode; HC, Healthy Controls; HD, Heidelberg NSS scale (<xref ref-type="bibr" rid="B29">29</xref>); ICC, intra class correlation; IRR, interrater reliability; m, male; MATRICS, Measurement and Treatment Research to Improve Cognition in Schizophrenia; MCCB, MATRICS Cognitive Consensus Battery; NES, Neurological Evaluation Scale (<xref ref-type="bibr" rid="B62">62</xref>); NHSI, New Haven Schizophrenia Index; NR, non-remitters; OC, obstetric complications; PANSS, Positive and Negative Syndrome Scale; Pt(s), patient(s); R, remitters; SANS, Scale for the assessment of negative symptoms; SAPS, Scale for the assessment of positive symptoms; SARS, Simpson Angus Rating Scale; SCZ, Schizophrenia; SFRSS, Schneider First Rank Symptom Scale (<xref ref-type="bibr" rid="B63">63</xref>); SKT, &#x0201C;Syndrom Kurztest&#x0201D; (short test for the assessment of cognitive functioning); TD-scale, tardive dyskinesia scale; WCST, Wisconsin Card Sorting Test; NSS: Neurological Soft Signs</italic>.</p>
</table-wrap-foot>
</table-wrap>
<p>The number of patients included ranged from 10 to 126, with less than 20 patients in 7 studies; 15 studies dealt with FE patients. Patients suffering from bipolar disorder, major depressive disorder, affective disorders, delusional disorder, substance-induced psychotic disorders, and personality disorders accounted for 21 and 36% of participants in two studies (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B58">58</xref>); all remaining exclusively consisted of subjects suffering from schizophrenia.</p>
<p>Instruments for the assessment of NSS were mostly standardized and widely used scales, namely the Neurological Evaluation Scale [NES (<xref ref-type="bibr" rid="B62">62</xref>)], the Cambridge Neurological Inventory [CNI (<xref ref-type="bibr" rid="B61">61</xref>)], the Condensed Neurological Examination [CNE (<xref ref-type="bibr" rid="B60">60</xref>)], the Heidelberg Scale [HD (<xref ref-type="bibr" rid="B29">29</xref>)], and the Brief Motor Scale [BMI (<xref ref-type="bibr" rid="B59">59</xref>)]. The following six exceptions were made: Emsley et al. (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>) shortened the NES to 13 items, Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>) employed a standard neurological examination complemented by tests of sensory function and complex motor acts, Mittal et al. (<xref ref-type="bibr" rid="B46">46</xref>) used the Quitkin scale (<xref ref-type="bibr" rid="B2">2</xref>), Tucker and Silberfarb (<xref ref-type="bibr" rid="B1">1</xref>) applied 4, Torrey (<xref ref-type="bibr" rid="B56">56</xref>) and Wahlheim et al. (<xref ref-type="bibr" rid="B57">57</xref>) two single tests respectively.</p>
<p>Apart from adjustments and exceptions, the different NSS scales and scores are not comparable directly since the number of items differs between instruments as does the scoring (0&#x02013;1 to 0&#x02013;3 points) of the individual items. However, items and/or subscales are contrastable, especially with respect to motor sequencing, motor coordination, and sensory integration, which are the most relevant items concerning pathology in schizophrenia. These important components of NSS were assessed in almost all studies integrated in this review.</p>
<p>Ratings were performed by 2&#x02013;3 raters in half of the studies, achieving overall good interrater reliabilities (see Table <xref ref-type="table" rid="T1">1</xref>). One single rater applied the tests in the remaining 50%, which was mainly the case in older studies.</p>
<p>Catamnestic periods extended from a short-term of 2&#x02013;8&#x02009;weeks to a medium duration of 6&#x02009;months to 2&#x02009;years to long-term follow-ups of 5 and 6&#x02009;years (see Table <xref ref-type="table" rid="T1">1</xref>).</p>
</sec>
<sec id="S3-2">
<title>NSS during Follow-up</title>
<p>Researchers who included HC in their assessments unanimously reported that patients scored significantly worse than healthy comparison subjects [review by Dazzan and Murray (<xref ref-type="bibr" rid="B6">6</xref>)]. Table <xref ref-type="table" rid="T1">1</xref> indicates that 35% of all studies in this review compared to HC patients, all of which showed significant differences in NSS scores throughout.</p>
<p>For reasons of better comparison, we grouped all identified studies according to patients&#x02019; illness status and their NSS course (Table <xref ref-type="table" rid="T2">2</xref>). Independent of the number of patients included and the instruments used for the assessment of NSS, all studies on chronic schizophrenia showed that NSS remained stable or deteriorated, whereas studies on patients with a remitting course found that NSS decreased over time. The pattern also appears in the studies by Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>), in which both chronic and remitting patients participated. There are two exceptions, namely the studies by Jahn et al. (<xref ref-type="bibr" rid="B43">43</xref>) and Torrey (<xref ref-type="bibr" rid="B56">56</xref>) where mixed samples were included and the respective NSS results on follow-up are heterogeneous. Presumably the divide follows the above model, which, however, cannot be proven or rebuted.</p>
<table-wrap position="float" id="T2">
<label>Table 2</label>
<caption><p>Follow-up studies in schizophrenia and NSS course (decreasing &#x02013; stable &#x02013; increasing).</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="left">Decreasing neurological soft signs (NSS)</th>
<th valign="top" align="left">Stable NSS</th>
<th valign="top" align="left">Increasing NSS</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="13">First episode</td>
<td align="left" valign="top">Bachmann et al. (<xref ref-type="bibr" rid="B31">31</xref>)</td>
<td align="left" valign="top">Behere (<xref ref-type="bibr" rid="B34">34</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top" style="background-color:#FFF56D;">Boks et al. (<xref ref-type="bibr" rid="B35">35</xref>)</td>
<td align="left" valign="top" style="background-color:#FFF56D;">Boks et al.: with increasing medication (<xref ref-type="bibr" rid="B35">35</xref>)</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#FEC464;">Chan et al. (<xref ref-type="bibr" rid="B37">37</xref>): pats without negative symptoms</td>
<td align="left" valign="top" style="background-color:#FEC464;">Chan et al. (<xref ref-type="bibr" rid="B37">37</xref>): pats with negative symptoms</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#FEC464;">Chen et al. (<xref ref-type="bibr" rid="B39">39</xref>): motor signs only</td>
<td align="left" valign="top" style="background-color:#FEC464;">Chen et al. (<xref ref-type="bibr" rid="B39">39</xref>): all except motor signs</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#FEC464;">Cuesta et al. (<xref ref-type="bibr" rid="B40">40</xref>): clinically improved pats (16%)</td>
<td align="left" valign="top" style="background-color:#FEC464;">Cuesta et al. (<xref ref-type="bibr" rid="B40">40</xref>): stable pats (84%)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#FEC464;">Emsley et al. (<xref ref-type="bibr" rid="B41">41</xref>): motor sequencing initially</td>
<td align="left" valign="top" style="background-color:#FEC464;">Emsley et al. (<xref ref-type="bibr" rid="B41">41</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Emsley et al. (<xref ref-type="bibr" rid="B42">42</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Mangot and Sawant (<xref ref-type="bibr" rid="B45">45</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top" style="background-color:#FFF56D;">Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>)</td>
<td align="left" valign="top" style="background-color:#FFF56D;">Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>): with deteriorating course</td>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#FEC464;">Ojagbemi et al. (<xref ref-type="bibr" rid="B47">47</xref>): in good responders</td>
<td align="left" valign="top" style="background-color:#FEC464;">Ojagbemi et al. (<xref ref-type="bibr" rid="B47">47</xref>): only motor sequencing; in poor responders</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Scheffer (<xref ref-type="bibr" rid="B51">51</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#CDE6F1;">Prikryl et al. (<xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top" style="background-color:#CDE6F1;">Prikryl et al. (<xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>): with negative symptoms after initial decrease</td>
</tr>
<tr>
<td align="left" valign="top">Whitty et al. (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B58">58</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="6">Remitting course</td>
<td align="left" valign="top" style="background-color:#1D74B6;">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#1D74B6;">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#1D74B6;">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B53">53</xref>)</td>
</tr>
<tr>
<td align="left" valign="top">Sevincok and Topaloglu (<xref ref-type="bibr" rid="B54">54</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Tucker and Silberfarb (<xref ref-type="bibr" rid="B1">1</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top">Wahlheim et al. (<xref ref-type="bibr" rid="B57">57</xref>)</td>
<td align="left" valign="top"/>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="4">Chronic course</td>
<td align="left" valign="top"/>
<td align="left" valign="top">Buchanan et al. (<xref ref-type="bibr" rid="B36">36</xref>)</td>
<td align="left" valign="top">Chen et al. (<xref ref-type="bibr" rid="B38">38</xref>)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top" style="background-color:#1D74B6;">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B29">29</xref>)</td>
<td align="left" valign="top">Mittal et al. (<xref ref-type="bibr" rid="B46">46</xref>)</td>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top" style="background-color:#1D74B6;">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B52">52</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top" style="background-color:#1D74B6;">Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B53">53</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" colspan="4"><hr/></td>
</tr>
<tr>
<td align="left" valign="top" rowspan="3">Mixed group</td>
<td align="left" valign="top" style="background-color:#FEC464;">Jahn et al. (<xref ref-type="bibr" rid="B43">43</xref>)</td>
<td align="left" valign="top" style="background-color:#FEC464;">Jahn et al. (<xref ref-type="bibr" rid="B43">43</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top"/>
<td align="left" valign="top">Smith et al. (<xref ref-type="bibr" rid="B55">55</xref>)</td>
<td align="left" valign="top"/>
</tr>
<tr>
<td align="left" valign="top" style="background-color:#CDE6F1;">Torrey (<xref ref-type="bibr" rid="B56">56</xref>)</td>
<td align="left" valign="top" style="background-color:#CDE6F1;">Torrey (<xref ref-type="bibr" rid="B56">56</xref>)</td>
<td align="left" valign="top" style="background-color:#CDE6F1;">Torrey (<xref ref-type="bibr" rid="B56">56</xref>)</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The picture on FE patients is less clear. Whereas patients&#x02019; NSS status improved in several studies (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B58">58</xref>), the patients&#x02019; cohort fell into two subgroups in the majority of studies, mostly with one subgroup exhibiting an improving and another a stable NSS course over time.</p>
<p>Only Boks et al. (<xref ref-type="bibr" rid="B35">35</xref>) and Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>) reported a division into two subgroups with stable and deteriorating NSS, and Prikryl et al. (<xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>) described two subgroups with improving and worsening course, respectively. No change except for worsening of the glabellar reflex was observed in one study (<xref ref-type="bibr" rid="B51">51</xref>).</p>
</sec>
<sec id="S3-3">
<title>NSS Subscales during Follow-up</title>
<p>Change in total NSS&#x02014;if present&#x02014;was mostly accounted for by change in the motor system subscales, i.e., motor coordination and motor sequencing (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B58">58</xref>). Cuesta et al. (<xref ref-type="bibr" rid="B40">40</xref>) reported an improvement in all subscales except for frontal signs.</p>
<p>Emsley et al. (<xref ref-type="bibr" rid="B41">41</xref>) reported a decrease of motor signs during the first 3&#x02009;months of treatment with a subsequent return to initial values. Accordingly, in their second study, the group (<xref ref-type="bibr" rid="B42">42</xref>) did not note a drop in motor signs despite of a significant decline in total NSS. Other authors divided their samples into remitters and non-remitters and reported a decrease of motor signs being related to a remitting course (50 plus sensory integration; 29 plus spatial orientation). Likewise, in a FE study (<xref ref-type="bibr" rid="B31">31</xref>) subgroups arose after 1&#x02009;year, which were distinguishable by the subscales motor coordination, motor sequencing, and sensory integration. The sensory integration subscale also added to an overall change in NSS scores in two other studies (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B38">38</xref>), right-left and spatial orientation did so in one (<xref ref-type="bibr" rid="B31">31</xref>). Moreover, one group detected a non-significant decrease of the above-indicated subscale scores (<xref ref-type="bibr" rid="B54">54</xref>) and another group described a concordant finding for sensory integration (<xref ref-type="bibr" rid="B34">34</xref>).</p>
<p>Among the groups that did not detect any NSS change over time, Smith et al. (<xref ref-type="bibr" rid="B55">55</xref>) pointed out the relatively high stability of motor signs as opposed to the low stability of sensory integration signs in chronic patients. In FE individuals two groups found stability of motor signs (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B47">47</xref>).</p>
<p>Chen et al. (<xref ref-type="bibr" rid="B38">38</xref>) reported deterioration of motor coordination, sensory integration, and disinhibition in a complete sample of chronic patients. Unfortunately, Boks et al. (<xref ref-type="bibr" rid="B35">35</xref>), Mittal et al. (<xref ref-type="bibr" rid="B46">46</xref>), and Whitty et al. (<xref ref-type="bibr" rid="B30">30</xref>) did not give any information on subscales when there was an overall NSS deterioration. In the study by Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>), NSS increase was mostly related to corticospinal tract signs.</p>
</sec>
<sec id="S3-4">
<title>NSS, Symptoms, and Other Clinical Variables</title>
<p>Medication influences both clinical variables and NSS (see below). Nevertheless, the relationship between NSS and clinical variables will be discussed separately.</p>
<p>Two studies did not assess or indicate psychopathology. The Scale for the Assessment of Negative Symptoms, and the Scale for the Assessment of Positive Symptoms were used by two groups, completed by the Present State Examination (PSE-9) once, whereas all remaining researchers employed the Positive and Negative Syndrome Scale (PANSS) or the Brief Psychiatric Rating Scale (BPRS). The respective scores at study inception and follow-up are given by 13 authors, whereas, 6 reported incomplete data (see Table <xref ref-type="table" rid="T1">1</xref>). Scores are essentially comparable in the sense that (a) scores assessed with the same instrument fall into the same range, (b) the absolute follow-up scores are even similar, (c) acutely ill patients&#x02019; score decrease over time, and (d) scores of chronic patients or of those who were assessed in a stable condition remain widely unchanged.</p>
<p>Several authors have reported an improvement of NSS in parallel to a <italic>decrease of symptoms or treatment response</italic>, respectively (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B29">29</xref>&#x02013;<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B42">42</xref>&#x02013;<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B46">46</xref>&#x02013;<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B56">56</xref>&#x02013;<xref ref-type="bibr" rid="B58">58</xref>). This pattern was even found in patients without symptom change (<xref ref-type="bibr" rid="B44">44</xref>) and in a subgroup without negative symptoms (<xref ref-type="bibr" rid="B34">34</xref>). Furthermore, associations of remission and motor signs were described (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B30">30</xref>), whereas remitters in the studies by Prikryl et al. (<xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>) exhibited lower total, sensory integration, and motor sequencing scores. Also severity of illness and lower social functioning (<xref ref-type="bibr" rid="B44">44</xref>) or severity of illness, except for motor sequencing, correlated with NSS (<xref ref-type="bibr" rid="B47">47</xref>). Other researchers did not find an association between NSS with symptoms in first-episode (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B45">45</xref>) or chronic patients (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B55">55</xref>). In two studies, even a deterioration of NSS in chronically ill (<xref ref-type="bibr" rid="B38">38</xref>) and of corticospinal functions in non-remitting FE patients was detected (<xref ref-type="bibr" rid="B44">44</xref>).</p>
<p><italic>Positive symptoms</italic> were only addressed separately in a few studies. Scheffer (<xref ref-type="bibr" rid="B51">51</xref>) reported significant associations of NSS change in motor coordination, sequencing of complex motor acts, and sensory integration with change in the positive subscale (and total BPRS score, as discussed above). This is supported by findings of significant positive correlations between NSS and positive symptoms in two studies (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>) and of balance and positive symptoms in another study (<xref ref-type="bibr" rid="B41">41</xref>). Results by Chen et al. (<xref ref-type="bibr" rid="B38">38</xref>) did not underline the aforementioned findings. Even after a split into high and low positive symptoms no association with NSS emerged.</p>
<p>Researchers reported more extensively on <italic>negative symptoms</italic> compared to other symptoms present at the catamnestic examination. Many groups found a positive or increasing correlation over time between total NSS scores and negative symptoms (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B58">58</xref>), as well as correlations between motor signs and negative symptoms (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B47">47</xref>). One group described partial correlations of negative symptoms with primitive reflexes (<xref ref-type="bibr" rid="B34">34</xref>). Yet others reported an association of NSS with discomfort (<xref ref-type="bibr" rid="B46">46</xref>) or with negative and disorganized symptoms (<xref ref-type="bibr" rid="B47">47</xref>). Some groups depicted constancy of negative symptoms and NSS over time (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>) in diverse patient samples and even in individuals with variations of NSS. Whitty et al. (<xref ref-type="bibr" rid="B30">30</xref>) even posit that negative symptoms rather than positive or general psychopathological symptoms may predict NSS.</p>
<p>Some authors considered <italic>further symptoms</italic> in their reports. They found an association between rapid movement or convergence and depression or anxiety (<xref ref-type="bibr" rid="B41">41</xref>), of total NSS with disorganization symptoms (<xref ref-type="bibr" rid="B42">42</xref>) on the one hand and a negative correlation of NSS and discomfort (<xref ref-type="bibr" rid="B46">46</xref>) on the other hand.</p>
<p>The meta-analysis by Chan et al. (<xref ref-type="bibr" rid="B16">16</xref>) already reported a strong relationship between NSS and symptoms in general. This notion is confirmed and extended by longitudinal studies which argue that the association even increases over time, the longer the more, and holds true mostly for negative symptoms.</p>
<p>Results on outcome are thus divergent: authors report (a) either no difference between good and poor outcome patients with respect to motor signs (<xref ref-type="bibr" rid="B39">39</xref>) or (b) better outcome measures in patients who complied with treatment and exhibited decreasing NSS scores (<xref ref-type="bibr" rid="B31">31</xref>); along these lines, remission was inversely correlated to NSS as described by two groups (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>). In terms of prediction, bidirectional relationships are possible: NSS predict symptomatology (<xref ref-type="bibr" rid="B46">46</xref>), positive and negative symptoms, as well as other parameters predict increasing NSS (<xref ref-type="bibr" rid="B30">30</xref>). From the perspective of outcome, there seems to be a close relationship to NSS and psychopathology, in the sense that both higher NSS and higher psychopathology are related to a worse outcome.</p>
<p><italic>Cognitive functioning</italic> was addressed in several studies. Chan et al. (<xref ref-type="bibr" rid="B37">37</xref>) did not find any group&#x0002A;time effect with NSS and overall cognitive parameters. However, over time, NSS correlated with poorer performance on the letter&#x02013;number span test. Their group also reported paralleling trends of NSS and Winsconsin Card Sorting Test (WCST) perseverative errors in both patient groups as well as higher scores in logical memory, delayed logical memory, and WCST category, which authors relate to worse motor coordination and total NSS scores. In another study (<xref ref-type="bibr" rid="B42">42</xref>), working memory amelioration was predicted by sensory integration and motor coordination, whereas motor sequencing was predicted by working memory. Jahn et al. (<xref ref-type="bibr" rid="B43">43</xref>) even found correlations between NSS and all subscales of the modified WCST. Another study from Germany (<xref ref-type="bibr" rid="B52">52</xref>) reported a parallelizing improvement of both NSS and cognitive parameters, namely d2, Tower of Toronto test, SKT: delayed recall (Syndrom-Kurzztest, short assessment of cognitive performance), and SKT: delayed recognition. Further nonsignificant improvements occurred in the Tower of London test and SKT: immediate recall. Along these lines worsening of higher cognitive functioning paralleled higher hard signs (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B46">46</xref>), and patients with NSS&#x02014;as opposed to those without&#x02014;exhibited negative symptoms and cognitive disorganization (<xref ref-type="bibr" rid="B57">57</xref>). Respective correlations emerged in cross-sectional research (<xref ref-type="bibr" rid="B64">64</xref>&#x02013;<xref ref-type="bibr" rid="B68">68</xref>).</p>
<p>Patients included in the reviewed study were of relatively young <italic>age</italic>. None of the authors discussed age with respect to NSS. The same holds true for <italic>gender</italic>. The literature does not report any influence of sex on NSS. Neither did we detect any influence. <italic>Family history</italic> was addressed by Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>) who found an NSS deterioration in a subgroup with first-degree relatives who suffered from a psychiatric disease. The same authors reported a worsening of NSS in patients with a history of <italic>obstetric complications</italic>. A relationship between <italic>level of education</italic> and NSS on follow-up was reported by two groups (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B30">30</xref>).</p>
<p><italic>Handedness</italic> was examined where indicated in Table <xref ref-type="table" rid="T1">1</xref>. Whereas our group did not detect any influence of handedness on NSS, Whitty et al. (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B30">30</xref>) found higher NSS in mixed handers. The latter may be related to a common basis of both, mixed-handedness and NSS, consisting of still ill-defined neurological abnormalities.</p>
<p>Several authors addressed the <italic>duration of untreated psychosis</italic> (DUP) which was positively associated with NSS (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B30">30</xref>) and negative symptoms or with motor symptoms only (<xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B41">41</xref>). Similar associations arose with the overall <italic>duration of illness</italic> (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Whitty et al. (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B30">30</xref>) even posit that the DUP predicts catamnestic levels of NSS.</p>
<p><italic>Alcohol and substance use</italic> were exclusion criteria in almost all studies, thus making the study population less representative. When this was not the case, alcohol did not influence NSS (<xref ref-type="bibr" rid="B57">57</xref>) or, together with negative symptoms, predicted higher NSS scores (<xref ref-type="bibr" rid="B58">58</xref>, <xref ref-type="bibr" rid="B30">30</xref>). The latter finding is supported by the literature (<xref ref-type="bibr" rid="B69">69</xref>), stating that drug and alcohol abuse are associated with more neurological abnormalities in schizophrenia.</p>
</sec>
<sec id="S3-5">
<title>NSS, Medication, and Side-Effects (SE)</title>
<p>Patients were treated with typical neuroleptics in 10 studies, with atypical compounds in 5 studies, and with any of both or a mixture in the remaining 11 studies, where authors not always gave the respective information or, e.g., just displayed chlorpromazine-equivalents.</p>
<p>Five groups reported on a sample of antipsychotic-na&#x000EF;ve or about 90% medication-na&#x000EF;ve patients; another two groups included antipsychotic-na&#x000EF;ve individuals but to a lesser extent (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B29">29</xref>). A washout phase prior to starting the study was reported by two researchers (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B54">54</xref>).</p>
<p>Dosages, where given, are not comparable between studies due to the different ways of reporting. Cuesta et al. (<xref ref-type="bibr" rid="B40">40</xref>), who used different antipsychotics or combinations, explicitly stated that there was significant NSS improvement over time independent of the type of medication, whereas Smith et al. (<xref ref-type="bibr" rid="B55">55</xref>) observed a trend toward lower NSS scores on atypical antipsychotics.</p>
<p>Whether or not antipsychotic medication exerts an effect on NSS can neither be proven nor disproven because the effect can only be generated indirectly. Although there is no indication regarding different effects of typical versus atypical compounds, evidence from the reviewed studies points toward different medication effects:
<list list-type="simple">
<list-item><label>(a)</label> <p>a positive influence of medication on NSS in terms of a decrease mostly stems from FE patients (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B58">58</xref>), but also from those with a longer-standing illness (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). Others found that medication intake was associated with less motor signs as opposed to a non-medicated status (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B58">58</xref>).</p></list-item>
<list-item><label>(b)</label> <p>partial positive effects were reported as well in FE and remitting versus non-remitting patients (<xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>).</p></list-item>
<list-item><label>(c)</label> <p>no relationship arose between NSS daily dose or type of antipsychotic compound (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B55">55</xref>).</p></list-item>
<list-item><label>(d)</label> <p>medication non-response and non-remitting NSS scores were related in studies on FE (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B49">49</xref>) and on chronic patients (<xref ref-type="bibr" rid="B36">36</xref>). One group reported that the association pertained to all subscales except sensory integration.</p></list-item>
<list-item><label>(e)</label> <p>two studies reported a relation between lifetime exposure to medication and less NSS change or even NSS increase in medication non-responders (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B44">44</xref>).</p></list-item>
</list></p>
<p>In summary, medicated patients seem to fall into at least two subgroups, namely one which improves clinically and in terms of NSS, and another which exhibits stable and/or worsening psychopathology as well as NSS. Possibly, the effect of medication may be related to the stage of illness and the overall magnitude of NSS which have been said to be predictors toward response to medication (<xref ref-type="bibr" rid="B70">70</xref>). Despite the diverse results, there is thus room for supporting the notion that antipsychotic compounds exert a protective effect on NSS (<xref ref-type="bibr" rid="B6">6</xref>). Already, Heinrichs and Buchanan (<xref ref-type="bibr" rid="B14">14</xref>) argued similarly by reporting that medicated patients exhibited fewer signs.</p>
<p>Consequentially, the relationship between clinical response to medication and NSS improvement&#x02014;or non-improvement, respectively&#x02014;leads to the assumption of a common underlying factor. For example, this may be the effect of antipsychotics on brain structure as reviewed by Scherk and Falkai (<xref ref-type="bibr" rid="B71">71</xref>). Ultimately though, the link between medication, brain structure, and NSS has not been located yet.</p>
<p>Side-effects of medication were assessed by 15 groups, using widely accepted instruments. Six authors indicated that no SE were present, five others did not give any results, hereby suggesting that non-reporting is due to a lack of significant pathology. A minority of six groups reported associations between NSS and extrapyramidal side-effects: a positive correlation on follow-up (<xref ref-type="bibr" rid="B47">47</xref>), a relationship to motor signs (<xref ref-type="bibr" rid="B44">44</xref>), to motor signs on 2-year follow-up (<xref ref-type="bibr" rid="B41">41</xref>), to sensory integration (<xref ref-type="bibr" rid="B45">45</xref>), or to stable, i.e., higher NSS (<xref ref-type="bibr" rid="B57">57</xref>). A significant increase of tardive dyskinesia on follow-up was observed in haloperidole treatment (<xref ref-type="bibr" rid="B36">36</xref>).</p>
</sec>
<sec id="S3-6">
<title>NSS and Ethnicity</title>
<p>The presented follow-up studies on NSS in schizophrenia were performed in different countries on four continents, namely, (North) America, Europe, Asia, and Africa. So far, study results do not show any pattern in favoring or contradicting an association of NSS and ethnicity, although more studies are warranted. For now, there is reason to assume that NSS may be remarkably similar across countries and ethnicities (<xref ref-type="bibr" rid="B72">72</xref>).</p>
</sec>
<sec id="S3-7">
<title>Methodology of Studies</title>
<p>Representativeness of the reviewed studies is high for the following reasons: only two research groups included diagnostic groups other than schizophrenias, the majority of researchers followed patients for at least 6&#x02009;months, 47% of the studies focused on FE patients, and interrater reliability or intraclass correlation was high overall. Different assessment instruments do not seem to exert an influence: although different researchers have used different instruments, these were standardized and featured the same dimensions of NSS. Moreover, there is agreement in the literature on the relative importance of the different groups of NSS: motor signs, i.e., motor sequencing, complex motor tasks, and motor integration are of overriding importance as they usually account for the largest part of the total NSS score. Sensory integration on the other hand plays a minor role.</p>
</sec>
<sec id="S3-8">
<title>The Trait versus State Debate</title>
<p>As schizophrenia has a genetic basis in up to 50% of cases (<xref ref-type="bibr" rid="B9">9</xref>), NSS have been looked at as endophenotypes, i.e., markers which help to discover the underlying genetic basis. There is an assumption that the amount of NSS and the abnormality of the single sign may even discriminate sporadic and familial schizophrenia with more pronounced abnormalities in familial cases (<xref ref-type="bibr" rid="B51">51</xref>). Along these genetic lines, many studies have reported more NSS and higher item scores in patients&#x02019; relatives compared to HC; the closer the relative, the more explicit the abnormalities (<xref ref-type="bibr" rid="B21">21</xref>). On the other hand, according to Kinney et al. (<xref ref-type="bibr" rid="B73">73</xref>) and Rossi et al. (<xref ref-type="bibr" rid="B60">60</xref>) NSS have a small to modest share in the liability toward schizophrenia. Gureje Gureje (<xref ref-type="bibr" rid="B74">74</xref>) even stated that NSS might not be specific to schizophrenia but related to obstetrical complications in general. Madsen et al. (<xref ref-type="bibr" rid="B44">44</xref>) may reconcile the opposite views: in their study differences between patients and healthy subjects regarding frontal, cerebrospinal, and temporo-parietal functions became larger over time&#x02014;which was more prominent in patients with a positive family history. Similarly, Hyde et al. (<xref ref-type="bibr" rid="B75">75</xref>) claim that &#x0201C;frontal release signs&#x0201D; are influenced by both genetic and environmental factors.</p>
<p>Meehl (<xref ref-type="bibr" rid="B76">76</xref>) stated that NSS can only be considered to represent genetic markers if:
<list list-type="order">
<list-item><p>they are specific for schizophrenia, i.e., discriminate patients from HC and patients with other psychiatric diseases;</p></list-item>
<list-item><p>siblings show at least a tendency for differing from healthy subjects;</p></list-item>
<list-item><p>acutely ill and remitted patients are comparable; and</p></list-item>
<list-item><p>schizophrenia patients with varying degrees of severity do not differ regarding NSS.</p></list-item>
</list></p>
<p>Meehl&#x02019;s first requirement for a genetic marker partially holds true in NSS. There was congruence among the reviewed studies that patients exhibit more NSS than HC. This is supported by the literature including FE patients (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B77">77</xref>). However, NSS can also be detected in patients suffering from a number of other psychiatric diseases including bipolar disorder, obsessive&#x02013;compulsive disorder, borderline personality disorder (<xref ref-type="bibr" rid="B78">78</xref>&#x02013;<xref ref-type="bibr" rid="B80">80</xref>).</p>
<p>Meehl&#x02019;s second postulation is fulfilled. NSS were also detected in siblings, but were qualitatively and quantitatively less distinct, i.e., taking an intermediate position between HC and patients. This represents a strong argument for a trait or hereditary component as backed up by the literature on patients&#x02019; first-degree relatives (<xref ref-type="bibr" rid="B20">20</xref>), on twins (<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B24">24</xref>), and on off-spring (<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B27">27</xref>).</p>
<p>Requirement three demands comparability between acutely ill and remitted patients. Some studies in our review argue in favor of comparability by reporting completely stable NSS over time. This was the case even in four FE studies (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B51">51</xref>) and in studies on chronic patients (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B39">39</xref>, <xref ref-type="bibr" rid="B55">55</xref>). The other studies reported differences between subgroups. However, the above-indicated FE patients presented with a long duration of untreated illness and might already have crossed the border toward chronicity, e.g., in the study by Chen et al. (<xref ref-type="bibr" rid="B39">39</xref>) where DUP amounted to 474&#x02009;&#x000B1;&#x02009;768&#x02009;days. Along these lines, some authors suggested an interrelationship between NSS and duration of illness (<xref ref-type="bibr" rid="B81">81</xref>, <xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B84">84</xref>). Moreover, there was one report (<xref ref-type="bibr" rid="B38">38</xref>) on a clear deterioration of NSS in chronic patients and a further one on patients worsening on a trend level (<xref ref-type="bibr" rid="B44">44</xref>), related to a non-remitting course, a family history of psychotic disorder in a first-degree relative, obstetric complications, and male gender.</p>
<p>Further arguments in favor of non-comparability between acutely ill, remitted, and chronically ill patients arise from studies which showed NSS improvement over time in most or all patients, differences in phases of the disease and other varying factors notwithstanding. Several follow-up studies found NSS improvement, especially in FE patients (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B58">58</xref>) with respect to subscales in FE (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B34">34</xref>), in patients with a remitting course (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B49">49</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B57">57</xref>) with significant effects in two of the cited studies, and in patients who were unmedicated prior to study inclusion (<xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B54">54</xref>). Moreover, in the study by Sevincok and Topaloglu (<xref ref-type="bibr" rid="B54">54</xref>), patients who were unmedicated at first assessment and medicated at the second displayed an absolute decrease of NSS&#x02014;possibly due to the small number of patients the results did not reach statistical significance. In all probability, compliance plays a role toward improvement (<xref ref-type="bibr" rid="B31">31</xref>). As adherence most likely is particularly high in patients who participate in a study, compliance presumably was present in the presented studies. Thus, at least at the onset of the illness and in remitting subtypes an NSS state component is present and expressed by fluctuations of NSS scores. Given the number of studies reporting fluctuating and decreasing NSS in FE and remitting patients, and the fact that only chronic patients experience stability or deterioration of NSS, the state component cannot be ignored. The fact that patients&#x02019; samples mostly divide into those with stable NSS and improving NSS at an early stage during their course of illness, is in line with schizophrenia not just representing one homogeneous disease but a group of entities, namely the &#x0201C;group of schizophrenias&#x0201D; as Bleuler put it (<xref ref-type="bibr" rid="B82">82</xref>). As the existence of subgroups is not debatable (<xref ref-type="bibr" rid="B83">83</xref>, <xref ref-type="bibr" rid="B85">85</xref>)&#x02014;subtypes may represent another argument for the existence of an NSS state feature in some patients but not others. Unfortunately, subtypes of the disorder and their influence over time were discussed by Schr&#x000F6;der et al. (<xref ref-type="bibr" rid="B29">29</xref>) only.</p>
<p>The fourth claim by Meehl states that schizophrenia patients with varying degrees of severity should not differ regarding NSS. Severity of patients&#x02019; illness in the different studies can either be compared by authors&#x02019; classification as FE, remitting, and chronic course or by looking at psychopathology. Whenever scores of well-known scales such as BPRS or PANSS were disclosed, their range was comparable. The latter comparison seems more valid because the former already is based on symptoms. With respect to psychopathology and NSS, differing patterns arise in those studies, which gave all necessary information. Some authors report a paralleling course of NSS and psychopathology in all patients (<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B46">46</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B58">58</xref>) or in subgroups (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B48">48</xref>&#x02013;<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B52">52</xref>). Others describe decreasing symptoms (except negative symptoms) but stable NSS (<xref ref-type="bibr" rid="B34">34</xref>) or the opposite, namely stable symptoms and decreasing (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B53">53</xref>) respectively increasing NSS (<xref ref-type="bibr" rid="B38">38</xref>). Yet, further studies found unchanged symptoms as well as NSS over time (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>).</p>
<p>With this diffuse pattern, Meehl&#x02019;s fourth demand is clearly not fulfilled. However, the pattern speaks in favor of a state component in NSS and the necessity to consider the stage of illness, as Smith et al. (<xref ref-type="bibr" rid="B55">55</xref>) reasoned: if a state dimension was predominant, the timing of NSS assessment would be important. This argument also calls into question the predictive value of NSS which was proposed by earlier authors (<xref ref-type="bibr" rid="B66">66</xref>, <xref ref-type="bibr" rid="B87">87</xref>).</p>
<p>Thus, only two of four of Meehl&#x02019;s claims are fulfilled and NSS qualify for both, a stable, and early-acquired trait and a fluctuating state component. The latter may possibly be related to the stage of the disease as well as to treatment.</p>
</sec>
</sec>
<sec id="S4">
<title>The Nature of NSS</title>
<p>In accordance with the literature, we argue that the NSS dimensions might be related to a neurointegrative defect in general (<xref ref-type="bibr" rid="B86">86</xref>), to dopamine-dependent pathways (<xref ref-type="bibr" rid="B87">87</xref>), or even more specifically to certain brain regions and circuits connecting them (<xref ref-type="bibr" rid="B11">11</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B88">88</xref>), be it at a subcortical level (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B89">89</xref>) or in terms of a cortical-subcortical pathway (<xref ref-type="bibr" rid="B90">90</xref>). Among the circuits in question, the fronto&#x02013;striatal&#x02013;thalamic route emerges as the most relevant toward motor signs which again seem to contribute overridingly toward overall NSS scores. According to our understanding the fronto&#x02013;striatal&#x02013;thalamic pathway is being complemented by integration of the cerebellum (<xref ref-type="bibr" rid="B91">91</xref>&#x02013;<xref ref-type="bibr" rid="B93">93</xref>), thus forming the cortico&#x02013;cerebellar&#x02013;thalamo&#x02013;cortical circuitry suggested by Andreasen et al. (<xref ref-type="bibr" rid="B94">94</xref>). Interestingly, Kong and colleagues (<xref ref-type="bibr" rid="B95">95</xref>) detected changes of the basal ganglia in ultra-high-risk subjects prior to manifestation of the disease. Changes of the basal ganglia in relation to NSS were already reported in 1998 (<xref ref-type="bibr" rid="B53">53</xref>) by applying SPECT. The authors showed that upregulation of dopamine d2 receptors under neuroleptic treatment may be involved.</p>
<p>These findings may partly explain the above cited effect of antipsychotics on brain structure as reviewed by Scherk and Falkai (<xref ref-type="bibr" rid="B71">71</xref>): typical and atypical antipsychotics exert varying effects on cortical gray matter and on almost all subcortical structures. The thalamus increases with both types of neuroleptics. This may reflect protective or regenerative processes related to the stabilization of NSS, especially of motor signs which most likely pertain to the cortico&#x02013;thalamo&#x02013;cerebellar&#x02013;cortical circuit.</p>
<p>As far as the remaining NSS are concerned, Carter et al. (<xref ref-type="bibr" rid="B96">96</xref>) suggested a disturbed integration of the sensory systems. Dazzan et al. (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B88">88</xref>) concluded that agreement concerning the neuro-dysfunctional basis of NSS is still missing.</p>
<p>However, similarities between longitudinal studies, in terms of general NSS elevation and change of NSS scores over time, clearly support a combination of state and trait aspects or a Janus-faced nature of NSS in schizophrenia. Unfortunately, the question of what underlies the state component has to remain open. At this point, innate and adaptive immune response may come in to play. As far as innate immune system alterations are concerned, prenatal maternal infections (<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B98">98</xref>) as well as obstetric complications, neonatal hypoxia, and brain injury lead to recruitment of cytokines which mediate inflammatory processes or represent a proinflammatory immune state in itself. Also, early strikes hitting the immune system may lead to a lifelong change in immune response and low-level neuroinflammation. For example, cytokines activate indoleamine 2,3-dioxygenase, which influences tryptophan, kynurenin, and serotonin in the central nervous system. As a consequence, serotonergic, noradrenergic, and glutamatergic neurotransmission may be modified (<xref ref-type="bibr" rid="B99">99</xref>). Changes in other inflammatory biomarkers (macrophages/monocytes, reduction in T cell numbers and proliferation, and alternations in T-helper cell 1 balance) may activate microglia, i.e., the intracerebral macrophages (<xref ref-type="bibr" rid="B98">98</xref>). Alterations of the immune response <italic>via</italic> inflammatory processes may also be related to infectious agents, which can cause acute or latent infections, namely, viruses and parasites, such as Human Herpesvirus 2, Borna Virus, <italic>Chlamydophila pneumoniae, Chlamydophila psittaci</italic>, and <italic>Toxoplasma gondii</italic> (<xref ref-type="bibr" rid="B100">100</xref>). Latent infections and reactivation of latent infections seem to be associated with acute disease phases in schizophrenia (<xref ref-type="bibr" rid="B31">31</xref>, <xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B102">102</xref>). Moreover, Human Endogenous Retrovirus may be activated in the genome by microbiological agents, immune mediators as mentioned above, and multiple other activators of the cell and thus be linked to schizophrenia in some individuals (<xref ref-type="bibr" rid="B103">103</xref>&#x02013;<xref ref-type="bibr" rid="B106">106</xref>).</p>
<p>All of the above-indicated factors may cause dysregulation of dopamine and further neurotransmitters, either directly or indirectly, and lead to impairments in cortico-subcortical networks.</p>
<p>These findings on infection and inflammation very much support a two-hit model of schizophrenia with a genetic or early acquired as well as a second-adapted factor forming the base of NSS and their trait and state aspects.</p>
<p>Above and beyond open questions on the nature of NSS, an integrative view of the different motor symptoms is warranted (<xref ref-type="bibr" rid="B107">107</xref>), as well as a taxonomy of symptoms in schizophrenia encompassing the sensory&#x02013;motor dimensions.</p>
</sec>
<sec id="S5">
<title>Conclusion</title>
<p>The literature on NSS in schizophrenia presents at least partially diverging results. On the one hand, research speaks in favor of NSS as being a stable entity, i.e., a trait: NSS are more pronounced in patients compared to their relatives; they are present at disease onset; there is a relationship with the more stable symptoms, namely negative and cognitive ones. Duration and chronicity of illness have also been linked with stability of NSS. On the other hand, there are arguments supporting a fluctuating aspect, especially of motor signs. Follow-up studies&#x02014;as summarized in this paper&#x02014;have reported modulations of NSS scores over time, especially in correlation with clinical improvement, in FE patients, and in the relapsing&#x02013;remitting subtype. Taken together, the evidence on NSS reconciles the dispute by suggesting that both components are involved, e.g., a trait or baseline component as well as a state component associated with psychotic exacerbations.</p>
<p>This underlying state-trait dichotomy of NSS is hardly influenced by the type of medication, supposedly apart from the lifetime load. Furthermore, in a state-trait feature, only the presence of the trait can be used as an endophenotype or a predictor, but not the quantitative expression, i.e., the state. The latter however, is called into question by studies which detected a paralleling course of symptoms and NSS, meaning that the volatility in terms of NSS decrease may serve as an outcome predictor.</p>
<p>Future research should raise the question of whether or not testing of NSS can be restricted to motor and sensory signs because these are the major subscales which account mostly for fluctuations in NSS scores. Moreover, apart from identifying the circuits which underlie the different NSS, researchers should study the mechanisms involved in the state component, i.e., undulations of NSS scores.</p>
</sec>
<sec id="S6" sec-type="author-contributor">
<title>Author Contributions</title>
<p>SB wrote and edited the manuscript. JS critically revised the different versions of the manuscript.</p>
</sec>
<sec id="S7">
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</body>
<back>
<ack>
<p>The authors would like to thank Dipl. Psych. Colette Guillaumier, who proofread the manuscript, for her very valuable help.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1"><label>1</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Tucker</surname> <given-names>GJ</given-names></name> <name><surname>Silberfarb</surname> <given-names>PM</given-names></name></person-group>. <article-title>Neurologic dysfunction in schizophrenia: significance for diagnostic practice</article-title>. In: <person-group person-group-type="editor"><name><surname>Akiskal</surname> <given-names>H</given-names></name> <name><surname>Webb</surname> <given-names>W</given-names></name></person-group>, editors. <source>Psychiatric Diagnosis: Exploration of Biological Predictors</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Spektrum</publisher-name> (<year>1978</year>). p. <fpage>453</fpage>&#x02013;<lpage>62</lpage>.</citation></ref>
<ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Quitkin</surname> <given-names>F</given-names></name> <name><surname>Rifkin</surname> <given-names>A</given-names></name> <name><surname>Klein</surname> <given-names>DF</given-names></name></person-group>. <article-title>Neurologic soft signs in schizophrenia and character disorders</article-title>. <source>Arch Gen Psychiatry</source> (<year>1976</year>) <volume>33</volume>:<fpage>845</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1976.01770070075008</pub-id></citation></ref>
<ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname> <given-names>BT</given-names></name> <name><surname>Kinney</surname> <given-names>DK</given-names></name> <name><surname>Yurgelun-Todd</surname> <given-names>D</given-names></name></person-group>. <article-title>Neurologic abnormalities in schizophrenic patients and their families. I. comparison of schizophrenic, bipolar, and substance abuse patients and normal controls</article-title>. <source>Arch Gen Psychiatry</source> (<year>1986</year>) <volume>43</volume>:<fpage>657</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1986.01800070043006</pub-id><pub-id pub-id-type="pmid">3718168</pub-id></citation></ref>
<ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boks</surname> <given-names>MPM</given-names></name> <name><surname>Russo</surname> <given-names>S</given-names></name> <name><surname>Knegtering</surname> <given-names>R</given-names></name> <name><surname>van den Bosch</surname> <given-names>RJ</given-names></name></person-group>. <article-title>The specificity of neurological signs in schizophrenia: a review</article-title>. <source>Schizophr Res</source> (<year>2000</year>) <volume>43</volume>:<fpage>109</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1016/S0920-9964(99)00145-0</pub-id><pub-id pub-id-type="pmid">10858629</pub-id></citation></ref>
<ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevens</surname> <given-names>JR</given-names></name> <name><surname>Livermore</surname> <given-names>A</given-names></name></person-group>. <article-title>Telemetered EEG in schizophrenia: spectral analysis during abnormal behaviour episodes</article-title>. <source>J Neurol Neurosurg Psychiatry</source> (<year>1982</year>) <volume>45</volume>:<fpage>385</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="doi">10.1136/jnnp.45.5.385</pub-id><pub-id pub-id-type="pmid">7086451</pub-id></citation></ref>
<ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dazzan</surname> <given-names>P</given-names></name> <name><surname>Murray</surname> <given-names>RM</given-names></name></person-group>. <article-title>Neurological soft signs in first-episode psychosis: a systematic review</article-title>. <source>Br J Psychiatry</source> (<year>2002</year>) <volume>181</volume>:<fpage>S50</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.181.43.s50</pub-id><pub-id pub-id-type="pmid">12271801</pub-id></citation></ref>
<ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hertzig</surname> <given-names>M</given-names></name> <name><surname>Birch</surname> <given-names>H</given-names></name></person-group>. <article-title>Neurologic organization in psychiatrically disturbed adolescents. A comparative consideration of sex differences</article-title>. <source>Arch Gen Psychiatry</source> (<year>1968</year>) <volume>19</volume>:<fpage>528</fpage>&#x02013;<lpage>37</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1968.01740110016003</pub-id></citation></ref>
<ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rochford</surname> <given-names>JM</given-names></name> <name><surname>Detre</surname> <given-names>T</given-names></name> <name><surname>Tucker</surname> <given-names>GJ</given-names></name> <name><surname>Harrow</surname> <given-names>M</given-names></name></person-group>. <article-title>Neuropsychological impairments in functional psychiatric diseases</article-title>. <source>Arch Gen Psychiatry</source> (<year>1970</year>) <volume>22</volume>:<fpage>114</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1970.01740260018003</pub-id></citation></ref>
<ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kennard</surname> <given-names>MA</given-names></name></person-group>. <article-title>Value ofequivocal signs in neurologic diagnosis</article-title>. <source>Neurology</source> (<year>1960</year>) <volume>10</volume>:<fpage>753</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="doi">10.1212/WNL.10.8.753</pub-id></citation></ref>
<ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>SM</given-names></name> <name><surname>Ludwig</surname> <given-names>AM</given-names></name></person-group>. <article-title>Neurological soft signs and psychopathology: incidence in diagnostic groups</article-title>. <source>Can J Psychiatry</source> (<year>1979</year>) <volume>24</volume>:<fpage>668</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="doi">10.1177/070674377902400711</pub-id><pub-id pub-id-type="pmid">42480</pub-id></citation></ref>
<ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boks</surname> <given-names>MPM</given-names></name> <name><surname>Liddle</surname> <given-names>PF</given-names></name> <name><surname>Burgerhof</surname> <given-names>JGM</given-names></name> <name><surname>Knegtering</surname> <given-names>R</given-names></name> <name><surname>van den Bosch</surname> <given-names>RJ</given-names></name></person-group>. <article-title>Neurological soft signs discriminating mood disorders from first episode schizophrenia</article-title>. <source>Acta Psychiatr Scand</source> (<year>2004</year>) <volume>110</volume>:<fpage>29</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0447.2004.00298.x</pub-id><pub-id pub-id-type="pmid">15180777</pub-id></citation></ref>
<ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mergl</surname> <given-names>R</given-names></name> <name><surname>Hegerl</surname> <given-names>U</given-names></name></person-group>. <article-title>Neurological soft signs in patients with obsessive-compulsive disorder</article-title>. <source>Fortschr Neurol Psychiatr</source> (<year>2005</year>) <volume>73</volume>:<fpage>504</fpage>&#x02013;<lpage>16</lpage>.<pub-id pub-id-type="doi">10.1055/s-2004-830173</pub-id></citation></ref>
<ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De la Fuente</surname> <given-names>JM</given-names></name> <name><surname>Bobes</surname> <given-names>J</given-names></name> <name><surname>Vizuete</surname> <given-names>C</given-names></name> <name><surname>Bascaran</surname> <given-names>MT</given-names></name> <name><surname>Morl&#x000E1;n</surname> <given-names>I</given-names></name> <name><surname>Mendlewicz</surname> <given-names>J</given-names></name></person-group>. <article-title>Neurologic soft signs in borderline personality disorder</article-title>. <source>J Clin Psychiatry</source> (<year>2006</year>) <volume>67</volume>:<fpage>541</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.4088/JCP.v67n0404</pub-id></citation></ref>
<ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinrichs</surname> <given-names>DW</given-names></name> <name><surname>Buchanan</surname> <given-names>RW</given-names></name></person-group>. <article-title>Significance and meaning of neurological signs in schizophrenia</article-title>. <source>Am J Psychiatry</source> (<year>1988</year>) <volume>145</volume>:<fpage>11</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1176/ajp.145.1.11</pub-id></citation></ref>
<ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombin</surname> <given-names>I</given-names></name> <name><surname>Arango</surname> <given-names>C</given-names></name> <name><surname>Buchanan</surname> <given-names>RW</given-names></name></person-group>. <article-title>Significance and meaning of neurological signs in schizophrenia: two decades later</article-title>. <source>Schizophr Bull</source> (<year>2005</year>) <volume>31</volume>:<fpage>962</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbi028</pub-id><pub-id pub-id-type="pmid">15958818</pub-id></citation></ref>
<ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>RCK</given-names></name> <name><surname>Xu</surname> <given-names>T</given-names></name> <name><surname>Heinrichs</surname> <given-names>RW</given-names></name> <name><surname>Yu</surname> <given-names>Y</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name></person-group>. <article-title>Neurological soft signs in schizophrenia: a meta-analysis</article-title>. <source>Schizophr Bull</source> (<year>2010</year>) <volume>36</volume>:<fpage>1089</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbp011</pub-id><pub-id pub-id-type="pmid">19377058</pub-id></citation></ref>
<ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krebs</surname> <given-names>MO</given-names></name> <name><surname>Fayand</surname> <given-names>AG</given-names></name> <name><surname>Bourdel</surname> <given-names>MC</given-names></name> <name><surname>Dischamp</surname> <given-names>J</given-names></name> <name><surname>Olie</surname> <given-names>JP</given-names></name></person-group>. <article-title>Validity and factorial structure of a standardized examination for neurological soft-signs in schizophrenia</article-title>. <source>Schizophr Res</source> (<year>2000</year>) <volume>45</volume>:<fpage>245</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1016/S0920-9964(99)00206-6</pub-id></citation></ref>
<ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tosato</surname> <given-names>S</given-names></name> <name><surname>Dazzan</surname> <given-names>P</given-names></name></person-group>. <article-title>The psychopathology of schizophrenia and the presence of neurological soft signs: a review</article-title>. <source>Curr Opin Psychiatry</source> (<year>2005</year>) <volume>18</volume>:<fpage>285</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1097/01.yco.0000165599.90928.c7</pub-id><pub-id pub-id-type="pmid">16639153</pub-id></citation></ref>
<ref id="B19"><label>19</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kraepelin</surname> <given-names>E</given-names></name></person-group>. <source>Psychiatrie. Ein Lehrbuch f&#x000FC;r Studierende und &#x000C4;rzte. 8. Auflage, III. Band. Klinische Psychiatrie II</source>. <publisher-loc>Teil, Leipzig</publisher-loc>: <publisher-name>Johann Ambrosiums Barth</publisher-name> (<year>1913</year>). <fpage>751</fpage> p.</citation></ref>
<ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolff</surname> <given-names>AL</given-names></name> <name><surname>O&#x02019;Driscoll</surname> <given-names>GA</given-names></name></person-group>. <article-title>Motor deficits and schizophrenia: the evidence from neuroleptic-na&#x000EF;ve patients and populations at risk</article-title>. <source>J Psychiatry Neurosci</source> (<year>1999</year>) <volume>24</volume>:<fpage>304</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">10516797</pub-id></citation></ref>
<ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cantor Graae</surname> <given-names>E</given-names></name> <name><surname>McNeil</surname> <given-names>TF</given-names></name> <name><surname>Rickler</surname> <given-names>KC</given-names></name> <name><surname>Sj&#x000F6;str&#x000F6;m</surname> <given-names>K</given-names></name> <name><surname>Rawlings</surname> <given-names>R</given-names></name> <name><surname>Higgins</surname> <given-names>ES</given-names></name> <etal/></person-group> <article-title>Are neurological abnormalities in well discordant monozygotic cotwins of schizophrenic subjects the result of perinatal trauma?</article-title> <source>Am J Psychiatry</source> (<year>1994</year>) <volume>151</volume>:<fpage>1194</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1176/ajp.151.8.1194</pub-id></citation></ref>
<ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niethammer</surname> <given-names>R</given-names></name> <name><surname>Weisbrod</surname> <given-names>M</given-names></name> <name><surname>Schiesser</surname> <given-names>S</given-names></name> <name><surname>Grothe</surname> <given-names>J</given-names></name> <name><surname>Maier</surname> <given-names>S</given-names></name> <name><surname>Peter</surname> <given-names>U</given-names></name> <etal/></person-group> <article-title>Genetic influence on laterality in schizophrenia? A twin study of neurological soft signs</article-title>. <source>Am J Psychiatry</source> (<year>2000</year>) <volume>157</volume>:<fpage>272</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.157.2.272</pub-id><pub-id pub-id-type="pmid">10671400</pub-id></citation></ref>
<ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname> <given-names>BD</given-names></name> <name><surname>Cotter</surname> <given-names>D</given-names></name> <name><surname>Denihan</surname> <given-names>C</given-names></name> <name><surname>Larkin</surname> <given-names>D</given-names></name> <name><surname>Murphy</surname> <given-names>P</given-names></name> <name><surname>Kinsella</surname> <given-names>A</given-names></name> <etal/></person-group> <article-title>Neurological soft signs and dermatoglyphic anomalies in twins with schizophrenia</article-title>. <source>Eur Psychiatry</source> (<year>2004</year>) <volume>19</volume>:<fpage>159</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="doi">10.1016/j.eurpsy.2003.10.006</pub-id><pub-id pub-id-type="pmid">15158923</pub-id></citation></ref>
<ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Picchioni</surname> <given-names>MM</given-names></name> <name><surname>Toulopoulou</surname> <given-names>T</given-names></name> <name><surname>Landau</surname> <given-names>S</given-names></name> <name><surname>Davies</surname> <given-names>N</given-names></name> <name><surname>Ribchester</surname> <given-names>T</given-names></name> <name><surname>Murray</surname> <given-names>RM</given-names></name></person-group>. <article-title>Neurological abnormalities in schizophrenic twins</article-title>. <source>Biol Psychiatry</source> (<year>2006</year>) <volume>59</volume>:<fpage>341</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.biopsych.2005.07.007</pub-id><pub-id pub-id-type="pmid">16169527</pub-id></citation></ref>
<ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fish</surname> <given-names>B</given-names></name> <name><surname>Hagin</surname> <given-names>R</given-names></name></person-group>. <article-title>Visual-motor disorders in infants at risk for schizophrenia</article-title>. <source>Arch Gen Psychiatry</source> (<year>1973</year>) <volume>28</volume>:<fpage>900</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1973.01750360110017</pub-id></citation></ref>
<ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname> <given-names>J</given-names></name> <name><surname>Hans</surname> <given-names>SL</given-names></name> <name><surname>Mednick</surname> <given-names>SA</given-names></name> <name><surname>Schulsinger</surname> <given-names>F</given-names></name> <name><surname>Michelsen</surname> <given-names>N</given-names></name></person-group>. <article-title>Neurological dysfunctioning in offspring of schizophrenics in Israel and Denmark. A replication analysis</article-title>. <source>Arch Gen Psychiatry</source> (<year>1985</year>) <volume>42</volume>:<fpage>753</fpage>&#x02013;<lpage>61</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1985.01790310015002</pub-id><pub-id pub-id-type="pmid">4015319</pub-id></citation></ref>
<ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lawrie</surname> <given-names>SM</given-names></name> <name><surname>Byrne</surname> <given-names>M</given-names></name> <name><surname>Miller</surname> <given-names>P</given-names></name> <name><surname>Hodges</surname> <given-names>A</given-names></name> <name><surname>Clafferty</surname> <given-names>RA</given-names></name> <name><surname>Cunningham Owens</surname> <given-names>DG</given-names></name> <etal/></person-group> <article-title>Neurodevelopmental indices and the development of psychotic symptoms in subjects at high risk of schizophrenia</article-title>. <source>Br J Psychiatry</source> (<year>2001</year>) <volume>178</volume>:<fpage>524</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.178.6.524</pub-id><pub-id pub-id-type="pmid">11388968</pub-id></citation></ref>
<ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weinberger</surname> <given-names>DR</given-names></name></person-group>. <article-title>From neuropathology to neurodevelopment</article-title>. <source>Lancet</source> (<year>1995</year>) <volume>346</volume>:<fpage>552</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/S0140-6736(95)91386-6</pub-id></citation></ref>
<ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name> <name><surname>Niethammer</surname> <given-names>R</given-names></name> <name><surname>Geider</surname> <given-names>FJ</given-names></name> <name><surname>Reitz</surname> <given-names>C</given-names></name> <name><surname>Binkert</surname> <given-names>M</given-names></name> <name><surname>Jauss</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Neurological soft signs in schizophrenia</article-title>. <source>Schizophr Res</source> (<year>1992</year>) <volume>6</volume>:<fpage>25</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1016/0920-9964(91)90017-L</pub-id></citation></ref>
<ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitty</surname> <given-names>P</given-names></name> <name><surname>Clarke</surname> <given-names>M</given-names></name> <name><surname>Browne</surname> <given-names>S</given-names></name> <name><surname>McTique</surname> <given-names>O</given-names></name> <name><surname>Kamali</surname> <given-names>M</given-names></name> <name><surname>Feeney</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena</article-title>. <source>Psychol Med</source> (<year>2003</year>) <volume>33</volume>:<fpage>1479</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="doi">10.1017/S0033291703008225</pub-id><pub-id pub-id-type="pmid">14672257</pub-id></citation></ref>
<ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Bottmer</surname> <given-names>C</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>S</given-names></name></person-group>. <article-title>Neurological soft signs in first-episode schizophrenia: a follow-up study</article-title>. <source>Am J Psychiatry</source> (<year>2005</year>) <volume>162</volume>:<fpage>2337</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.162.12.2337</pub-id><pub-id pub-id-type="pmid">16330599</pub-id></citation></ref>
<ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Degen</surname> <given-names>C</given-names></name> <name><surname>Geider</surname> <given-names>FJ</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name></person-group>. <article-title>Neurological soft signs in the clinical course of schizophrenia: results of a meta-analysis</article-title>. <source>Front Psychiatry</source> (<year>2014</year>) <volume>5</volume>:<fpage>185</fpage>.<pub-id pub-id-type="doi">10.3389/fpsyt.2014.00185</pub-id><pub-id pub-id-type="pmid">25566104</pub-id></citation></ref>
<ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fellick</surname> <given-names>J</given-names></name> <name><surname>Thompson</surname> <given-names>APJ</given-names></name> <name><surname>Sills</surname> <given-names>J</given-names></name> <name><surname>Hart</surname> <given-names>CA</given-names></name></person-group>. <article-title>Neurological soft signs in mainstream pupils</article-title>. <source>Arch Dis Child</source> (<year>2001</year>) <volume>85</volume>:<fpage>371</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="doi">10.1136/adc.85.5.371</pub-id><pub-id pub-id-type="pmid">11668095</pub-id></citation></ref>
<ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behere</surname> <given-names>RV</given-names></name></person-group>. <article-title>Dorsolateral prefrontal lobe volume and neurological soft signs as predictors of clinical social and functional outcome in schizophrenia: a longitudinal study</article-title>. <source>Indian J Psychiatry</source> (<year>2013</year>) <volume>55</volume>:<fpage>111</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.4103/0019-5545.111445</pub-id><pub-id pub-id-type="pmid">23825842</pub-id></citation></ref>
<ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boks</surname> <given-names>MPM</given-names></name> <name><surname>Selten</surname> <given-names>JP</given-names></name> <name><surname>Leask</surname> <given-names>S</given-names></name> <name><surname>Van den Bosch</surname> <given-names>RJ</given-names></name></person-group>. <article-title>The 2-year stability of neurological soft signs after a first episode of non-affective psychosis</article-title>. <source>Eur Psychiatry</source> (<year>2006</year>) <volume>21</volume>:<fpage>288</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1016/j.eurpsy.2005.09.004</pub-id><pub-id pub-id-type="pmid">16380235</pub-id></citation></ref>
<ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname> <given-names>RW</given-names></name> <name><surname>Koeppl</surname> <given-names>P</given-names></name> <name><surname>Breier</surname> <given-names>A</given-names></name></person-group>. <article-title>Stability of neurological signs with clozapine treatment</article-title>. <source>Biol Psychiatry</source> (<year>1994</year>) <volume>36</volume>:<fpage>198</fpage>&#x02013;<lpage>200</lpage>.<pub-id pub-id-type="doi">10.1016/0006-3223(94)91225-4</pub-id></citation></ref>
<ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname> <given-names>RCK</given-names></name> <name><surname>Geng</surname> <given-names>F</given-names></name> <name><surname>Lui</surname> <given-names>SSY</given-names></name> <name><surname>Wang</surname> <given-names>Y</given-names></name> <name><surname>Ho</surname> <given-names>KKY</given-names></name> <name><surname>Hung</surname> <given-names>KSY</given-names></name> <etal/></person-group> <article-title>Course of neurological soft signs in first-episode schizophrenia: relationsship with negative symptoms and cognitive performances</article-title>. <source>Sci Rep</source> (<year>2015</year>) <volume>5</volume>:<fpage>11053</fpage>.<pub-id pub-id-type="doi">10.1038/srep11053</pub-id></citation></ref>
<ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>EYH</given-names></name> <name><surname>Kwok</surname> <given-names>CL</given-names></name> <name><surname>Au</surname> <given-names>JWY</given-names></name> <name><surname>Chen</surname> <given-names>RYL</given-names></name> <name><surname>Lau</surname> <given-names>BST</given-names></name></person-group>. <article-title>Progressive deterioration of soft neurological signs in chronic schizophrenic patients</article-title>. <source>Acta Psychiatr Scand</source> (<year>2000</year>) <volume>102</volume>:<fpage>342</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1034/j.1600-0447.2000.102005342.x</pub-id><pub-id pub-id-type="pmid">11098805</pub-id></citation></ref>
<ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>EYH</given-names></name> <name><surname>Hui</surname> <given-names>CLM</given-names></name> <name><surname>Chan</surname> <given-names>RCK</given-names></name> <name><surname>Dunn</surname> <given-names>ELW</given-names></name> <name><surname>Miao</surname> <given-names>MYK</given-names></name> <name><surname>Yeung</surname> <given-names>WS</given-names></name> <etal/></person-group> <article-title>A 3-year prospective study of neurological soft signs in first-episode schizophrenia</article-title>. <source>Schizophr Res</source> (<year>2005</year>) <volume>75</volume>:<fpage>45</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2004.09.002</pub-id><pub-id pub-id-type="pmid">15820323</pub-id></citation></ref>
<ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cuesta</surname> <given-names>MJ</given-names></name> <name><surname>Jalon</surname> <given-names>EG</given-names></name> <name><surname>Campos</surname> <given-names>MS</given-names></name> <name><surname>Peralta</surname> <given-names>V</given-names></name></person-group>. <article-title>Cognitive effectiveness of olanzapine and risperidone in first episode psychosis</article-title>. <source>Br J Psychiatry</source> (<year>2009</year>) <volume>194</volume>:<fpage>439</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.bp.108.055137</pub-id></citation></ref>
<ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>R</given-names></name> <name><surname>Turner</surname> <given-names>HJ</given-names></name> <name><surname>Oosthuizen</surname> <given-names>PP</given-names></name> <name><surname>Carr</surname> <given-names>J</given-names></name></person-group>. <article-title>Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates</article-title>. <source>Schizophr Res</source> (<year>2005</year>) <volume>75</volume>:<fpage>35</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2004.06.014</pub-id><pub-id pub-id-type="pmid">15820322</pub-id></citation></ref>
<ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>R</given-names></name> <name><surname>Chiliza</surname> <given-names>B</given-names></name> <name><surname>Asmal</surname> <given-names>L</given-names></name> <name><surname>Kilian</surname> <given-names>S</given-names></name> <name><surname>Olivier</surname> <given-names>MR</given-names></name> <name><surname>Phahladira</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Neurological soft signs in first-episode schizophrenia: state- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects</article-title>. <source>Schizophr Res</source> (<year>2017</year>) <volume>188</volume>:<fpage>144</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2017.01.034</pub-id><pub-id pub-id-type="pmid">28130002</pub-id></citation></ref>
<ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname> <given-names>T</given-names></name> <name><surname>Hubmann</surname> <given-names>W</given-names></name> <name><surname>Karr</surname> <given-names>M</given-names></name> <name><surname>Mohr</surname> <given-names>F</given-names></name> <name><surname>Schlenker</surname> <given-names>R</given-names></name> <name><surname>Heidenreich</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses</article-title>. <source>Psychiatry Res</source> (<year>2006</year>) <volume>142</volume>:<fpage>191</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2002.12.003</pub-id><pub-id pub-id-type="pmid">16650902</pub-id></citation></ref>
<ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Madsen</surname> <given-names>AL</given-names></name> <name><surname>Vorstrup</surname> <given-names>S</given-names></name> <name><surname>Rubin</surname> <given-names>P</given-names></name> <name><surname>Larsen</surname> <given-names>JK</given-names></name> <name><surname>Hemmingsen</surname> <given-names>R</given-names></name></person-group>. <article-title>Neurological abnormalities in schizophrenic patients: a prospective follow-up study 5 years after first admission</article-title>. <source>Acta Psychiatr Scand</source> (<year>1999</year>) <volume>100</volume>:<fpage>119</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0447.1999.tb10832.x</pub-id><pub-id pub-id-type="pmid">10480197</pub-id></citation></ref>
<ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mangot</surname> <given-names>AG</given-names></name> <name><surname>Sawant</surname> <given-names>NS</given-names></name></person-group>. <article-title>First episode schizophrenia: neurological abnormalities and prognosis</article-title>. <source>German J Psychiatry</source> (<year>2013</year>) <volume>16</volume>:<fpage>75</fpage>&#x02013;<lpage>80</lpage>.</citation></ref>
<ref id="B46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mittal</surname> <given-names>VA</given-names></name> <name><surname>Hasenkamp</surname> <given-names>W</given-names></name> <name><surname>Sanfilipo</surname> <given-names>M</given-names></name> <name><surname>Wieland</surname> <given-names>S</given-names></name> <name><surname>Angrist</surname> <given-names>B</given-names></name> <name><surname>Rotrosen</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Relation of neurological soft signs to psychiatric symptoms in schizophrenia</article-title>. <source>Schizophr Res</source> (<year>2007</year>) <volume>94</volume>:<fpage>37</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2007.04.017</pub-id><pub-id pub-id-type="pmid">17543502</pub-id></citation></ref>
<ref id="B47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ojagbemi</surname> <given-names>A</given-names></name> <name><surname>Esan</surname> <given-names>O</given-names></name> <name><surname>Emsley</surname> <given-names>R</given-names></name> <name><surname>Gureje</surname> <given-names>O</given-names></name></person-group>. <article-title>Motor sequencing abnormalities are the trait marking neurological soft signs of schizophrenia</article-title>. <source>Neurosci Lett</source> (<year>2015</year>) <volume>600</volume>:<fpage>226</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="doi">10.1016/j.neulet.2015.06.028</pub-id></citation></ref>
<ref id="B48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prikryl</surname> <given-names>R</given-names></name> <name><surname>Ceskova</surname> <given-names>E</given-names></name> <name><surname>Kasparek</surname> <given-names>T</given-names></name> <name><surname>Kucerova</surname> <given-names>H</given-names></name></person-group>. <article-title>Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia</article-title>. <source>J Psychiatr Res</source> (<year>2006</year>) <volume>40</volume>:<fpage>141</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.jpsychires.2005.03.008</pub-id><pub-id pub-id-type="pmid">15907940</pub-id></citation></ref>
<ref id="B49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prikryl</surname> <given-names>R</given-names></name> <name><surname>Ceskova</surname> <given-names>E</given-names></name> <name><surname>Kasparek</surname> <given-names>T</given-names></name> <name><surname>Kucerova</surname> <given-names>H</given-names></name></person-group>. <article-title>Neurological soft signs and their relationship to 1-year outcome in first-episode schizophrenia</article-title>. <source>Eur Psychiatry</source> (<year>2007</year>) <volume>22</volume>:<fpage>449</fpage>&#x02013;<lpage>504</lpage>.<pub-id pub-id-type="doi">10.1016/j.eurpsy.2007.03.012</pub-id><pub-id pub-id-type="pmid">17614262</pub-id></citation></ref>
<ref id="B50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prikryl</surname> <given-names>R</given-names></name> <name><surname>Ceskova</surname> <given-names>E</given-names></name> <name><surname>Tronerova</surname> <given-names>S</given-names></name> <name><surname>Kasparek</surname> <given-names>T</given-names></name> <name><surname>Kucerova</surname> <given-names>HP</given-names></name> <name><surname>Ustohal</surname> <given-names>L</given-names></name> <etal/></person-group> <article-title>Dynamics of neurological soft signs and its relationship to clinical course in patients with first-episode schizophrenia</article-title>. <source>Psychiatry Res</source> (<year>2012</year>) <volume>200</volume>:<fpage>67</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2012.03.008</pub-id><pub-id pub-id-type="pmid">22494706</pub-id></citation></ref>
<ref id="B51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scheffer</surname> <given-names>RE</given-names></name></person-group>. <article-title>Abnormal neurological signs at the onset of psychosis</article-title>. <source>Schizophr Res</source> (<year>2004</year>) <volume>70</volume>:<fpage>19</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2003.10.007</pub-id></citation></ref>
<ref id="B52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name> <name><surname>Tittel</surname> <given-names>A</given-names></name> <name><surname>Stockert</surname> <given-names>A</given-names></name> <name><surname>Karr</surname> <given-names>M</given-names></name></person-group>. <article-title>Memory deficits in subsyndromes of chronic schizophrenia</article-title>. <source>Schizophr Res</source> (<year>1996</year>) <volume>21</volume>:<fpage>19</fpage>&#x02013;<lpage>26</lpage>.<pub-id pub-id-type="doi">10.1016/0920-9964(96)00027-8</pub-id><pub-id pub-id-type="pmid">8998272</pub-id></citation></ref>
<ref id="B53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name> <name><surname>Silvestri</surname> <given-names>S</given-names></name> <name><surname>Bubeck</surname> <given-names>B</given-names></name> <name><surname>Karr</surname> <given-names>M</given-names></name> <name><surname>Demisch</surname> <given-names>S</given-names></name> <name><surname>Scherrer</surname> <given-names>S</given-names></name> <etal/></person-group> <article-title>D2 Dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: a follow-up study with <sup>123</sup>I-iodobenzamide single photon emission computed tomography in the drug-na&#x000EF;ve state and after neuroleptic treatment</article-title>. <source>Biol Psychiatry</source> (<year>1998</year>) <volume>43</volume>:<fpage>660</fpage>&#x02013;<lpage>5</lpage>.</citation></ref>
<ref id="B54"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sevincok</surname> <given-names>L</given-names></name> <name><surname>Topaloglu</surname> <given-names>B</given-names></name></person-group>. <article-title>Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source> (<year>2006</year>) <volume>30</volume>:<fpage>141</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1016/j.pnpbp.2005.06.012</pub-id><pub-id pub-id-type="pmid">16023278</pub-id></citation></ref>
<ref id="B55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>RC</given-names></name> <name><surname>Hussain</surname> <given-names>MI</given-names></name> <name><surname>Chowdhury</surname> <given-names>SA</given-names></name> <name><surname>Stearns</surname> <given-names>A</given-names></name></person-group>. <article-title>Stability of neurological soft signs in chronically hospitalized schizophrenic patients</article-title>. <source>J Neuropsychiatry Clin Neurosci</source> (<year>1999</year>) <volume>11</volume>:<fpage>91</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1176/jnp.11.1.91</pub-id><pub-id pub-id-type="pmid">9990562</pub-id></citation></ref>
<ref id="B56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torrey</surname> <given-names>EF</given-names></name></person-group>. <article-title>Neurological abnormalities in schizophrenic patients</article-title>. <source>Biol Psychiatry</source> (<year>1980</year>) <volume>15</volume>:<fpage>381</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">7378515</pub-id></citation></ref>
<ref id="B57"><label>57</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Wahlheim</surname> <given-names>C</given-names></name> <name><surname>Hubmann</surname> <given-names>W</given-names></name> <name><surname>Mohr</surname> <given-names>F</given-names></name> <name><surname>Cohen</surname> <given-names>R</given-names></name> <name><surname>Schlenker</surname> <given-names>R</given-names></name> <name><surname>Werther</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>Pr&#x000E4;valenz und Stabilit&#x000E4;t neurologischer Soft Signs bei schizophrenen Patienten</article-title>. In: <person-group person-group-type="editor"><name><surname>Br&#x000E4;unig</surname> <given-names>P</given-names></name></person-group>, editor. <source>Motorische St&#x000F6;rungen bei schizophrenen Psychosen</source>. <publisher-loc>Stuttgart, New York</publisher-loc>: <publisher-name>Schattauer</publisher-name> (<year>1999</year>). p. <fpage>93</fpage>&#x02013;<lpage>106</lpage>.</citation></ref>
<ref id="B58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitty</surname> <given-names>P</given-names></name> <name><surname>Clarke</surname> <given-names>M</given-names></name> <name><surname>McTique</surname> <given-names>O</given-names></name> <name><surname>Browne</surname> <given-names>S</given-names></name> <name><surname>Gervin</surname> <given-names>M</given-names></name> <name><surname>Kamali</surname> <given-names>M</given-names></name> <etal/></person-group> <article-title>Diagnostic specificity and predictors of neurological soft signs in schizophrenia, bipolar disorder and other psychoses over the first 4 years of illness</article-title>. <source>Schizophr Res</source> (<year>2006</year>) <volume>86</volume>:<fpage>110</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2006.04.012</pub-id><pub-id pub-id-type="pmid">16765029</pub-id></citation></ref>
<ref id="B59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jahn</surname> <given-names>T</given-names></name> <name><surname>Cohen</surname> <given-names>R</given-names></name> <name><surname>Hubmann</surname> <given-names>W</given-names></name> <name><surname>Mohr</surname> <given-names>F</given-names></name> <name><surname>K&#x000F6;hler</surname> <given-names>I</given-names></name> <name><surname>Schlenker</surname> <given-names>R</given-names></name> <etal/></person-group> <article-title>The Brief Motor Scale (BMS) for the assessment of motor soft signs in schizophrenic psychoses and other psychiatric disorders</article-title>. <source>Psychiatry Res</source> (<year>2006</year>) <volume>142</volume>:<fpage>177</fpage>&#x02013;<lpage>89</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2002.12.002</pub-id><pub-id pub-id-type="pmid">16712950</pub-id></citation></ref>
<ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname> <given-names>A</given-names></name> <name><surname>De Cataldo</surname> <given-names>S</given-names></name> <name><surname>Di Michele</surname> <given-names>V</given-names></name> <name><surname>Manna</surname> <given-names>V</given-names></name> <name><surname>Ceccoli</surname> <given-names>S</given-names></name> <name><surname>Stratta</surname> <given-names>P</given-names></name> <etal/></person-group> <article-title>Neurological soft signs in schizophrenia</article-title>. <source>Br J Psychiatry</source> (<year>1990</year>) <volume>157</volume>:<fpage>735</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.157.5.735</pub-id></citation></ref>
<ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>EYH</given-names></name> <name><surname>Shapleske</surname> <given-names>J</given-names></name> <name><surname>Luque</surname> <given-names>R</given-names></name> <name><surname>McKenna</surname> <given-names>PJ</given-names></name> <name><surname>Hodges</surname> <given-names>JR</given-names></name> <name><surname>Calloway</surname> <given-names>SP</given-names></name> <etal/></person-group> <article-title>The Cambridge Neurological Inventory: a clinical instrument for assessment of soft neurological signs in psychiatric patients</article-title>. <source>Psychiatry Res</source> (<year>1995</year>) <volume>56</volume>:<fpage>183</fpage>&#x02013;<lpage>204</lpage>.<pub-id pub-id-type="doi">10.1016/0165-1781(95)02535-2</pub-id><pub-id pub-id-type="pmid">7667443</pub-id></citation></ref>
<ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchanan</surname> <given-names>RW</given-names></name> <name><surname>Heinrichs</surname> <given-names>DW</given-names></name></person-group>. <article-title>The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia</article-title>. <source>Psychiatry Res</source> (<year>1989</year>) <volume>27</volume>:<fpage>335</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/0165-1781(89)90148-0</pub-id></citation></ref>
<ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Astrachan</surname> <given-names>BM</given-names></name> <name><surname>Harrow</surname> <given-names>M</given-names></name> <name><surname>Adler</surname> <given-names>D</given-names></name> <name><surname>Brauer</surname> <given-names>L</given-names></name> <name><surname>Schwartz</surname> <given-names>A</given-names></name> <name><surname>Schwartz</surname> <given-names>C</given-names></name> <etal/></person-group> <article-title>A checklist for the diagnosis of schizophrenia</article-title>. <source>Br J Psychiatry</source> (<year>1972</year>) <volume>121</volume>:<fpage>529</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.121.5.529</pub-id></citation></ref>
<ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arango</surname> <given-names>C</given-names></name> <name><surname>Kirkpatrick</surname> <given-names>B</given-names></name> <name><surname>Buchanan</surname> <given-names>RW</given-names></name></person-group>. <article-title>Neurological signs and the heterogeneity of schizophrenia</article-title>. <source>Am J Psychiatry</source> (<year>2000</year>) <volume>157</volume>:<fpage>560</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1176/appi.ajp.157.4.560</pub-id><pub-id pub-id-type="pmid">10739414</pub-id></citation></ref>
<ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bersani</surname> <given-names>G</given-names></name> <name><surname>Clemente</surname> <given-names>R</given-names></name> <name><surname>Gherardelli</surname> <given-names>S</given-names></name> <name><surname>Pancheri</surname> <given-names>P</given-names></name></person-group>. <article-title>Deficit of executive functions in schizophrenia: relationship to neurological soft signs and psychopathology</article-title>. <source>Psychopathology</source> (<year>2004</year>) <volume>37</volume>:<fpage>118</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="doi">10.1159/000078610</pub-id><pub-id pub-id-type="pmid">15153743</pub-id></citation></ref>
<ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolakowska</surname> <given-names>T</given-names></name> <name><surname>Williams</surname> <given-names>AO</given-names></name> <name><surname>Jambor</surname> <given-names>K</given-names></name> <name><surname>Ardern</surname> <given-names>M</given-names></name></person-group>. <article-title>Schizophrenia with good and poor outcome. III: neurological &#x02018;soft&#x02019; signs, cognitive impairment and their clinical significance</article-title>. <source>Br J Psychiatry</source> (<year>1985</year>) <volume>146</volume>:<fpage>348</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.146.4.348</pub-id></citation></ref>
<ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liddle</surname> <given-names>PF</given-names></name></person-group>. <article-title>Schizophrenic syndromes, cognitive performance and neurological dysfunction</article-title>. <source>Psychol Med</source> (<year>1987</year>) <volume>17</volume>:<fpage>49</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1017/S0033291700012976</pub-id><pub-id pub-id-type="pmid">3575577</pub-id></citation></ref>
<ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname> <given-names>AH</given-names></name> <name><surname>Voruganti</surname> <given-names>LN</given-names></name> <name><surname>Heslegrave</surname> <given-names>RJ</given-names></name> <name><surname>Awad</surname> <given-names>AG</given-names></name></person-group>. <article-title>Neurocognitive deficits and neurological signs in schizophrenia</article-title>. <source>Schizophr Res</source> (<year>1997</year>) <volume>23</volume>:<fpage>139</fpage>&#x02013;<lpage>46</lpage>.<pub-id pub-id-type="doi">10.1016/S0920-9964(96)00095-3</pub-id></citation></ref>
<ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Keenan</surname> <given-names>E</given-names></name> <name><surname>O&#x02019;Donnell</surname> <given-names>C</given-names></name> <name><surname>Sinanan</surname> <given-names>K</given-names></name> <name><surname>O&#x02019;Callaghan</surname> <given-names>E</given-names></name></person-group>. <article-title>Severity of alcohol dependence and it&#x02019;s relationship to neurological soft signs, neuropsychological impairment and family history</article-title>. <source>Acta Psychiatr Scand</source> (<year>1997</year>) <volume>95</volume>:<fpage>272</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0447.1997.tb09631.x</pub-id></citation></ref>
<ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname> <given-names>AG</given-names></name></person-group>. <article-title>Drug therapy in schizophrenia &#x02013; variability of outcome and prediction of response</article-title>. <source>Can J Psychiatry</source> (<year>1989</year>) <volume>34</volume>:<fpage>711</fpage>&#x02013;<lpage>20</lpage>.<pub-id pub-id-type="doi">10.1177/070674378903400716</pub-id></citation></ref>
<ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scherk</surname> <given-names>H</given-names></name> <name><surname>Falkai</surname> <given-names>P</given-names></name></person-group>. <article-title>Effects of antipsychotics on brain structure</article-title>. <source>Curr Opin Psychiatry</source> (<year>2006</year>) <volume>19</volume>:<fpage>145</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1097/01.yco.0000214339.06507.d8</pub-id></citation></ref>
<ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname> <given-names>RA</given-names></name> <name><surname>Niehaus</surname> <given-names>DJ</given-names></name> <name><surname>Mbanga</surname> <given-names>N</given-names></name> <name><surname>Oosthuizen</surname> <given-names>PP</given-names></name> <name><surname>Stein</surname> <given-names>DJ</given-names></name> <name><surname>Maritz</surname> <given-names>JS</given-names></name> <etal/></person-group> <article-title>The factor structue for positiv and negative symptoms in South African Shoas patients with schizophrenia</article-title>. <source>Schizophr Res</source> (<year>2001</year>) <volume>47</volume>:<fpage>149</fpage>&#x02013;<lpage>57</lpage>.<pub-id pub-id-type="doi">10.1016/S0920-9964(00)00010-4</pub-id></citation></ref>
<ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kinney</surname> <given-names>DK</given-names></name> <name><surname>Woods</surname> <given-names>BT</given-names></name> <name><surname>Yurgelun-Todd</surname> <given-names>D</given-names></name></person-group>. <article-title>Neurologic abnormalities in schizophrenic patients and their families. II. Neurologic and psychiatric findings in relatives</article-title>. <source>Arch Gen Psychiatry</source> (<year>1986</year>) <volume>43</volume>:<fpage>665</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1986.01800070051007</pub-id><pub-id pub-id-type="pmid">3718169</pub-id></citation></ref>
<ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gureje Gureje</surname> <given-names>O</given-names></name></person-group>. <article-title>Tardive dyskinesia in schizophrenics: prevalence, distribution and relationship to neurological &#x02018;&#x02018;soft&#x02019;&#x02019; signs in Nigerian patients</article-title>. <source>Acta Psychiatr Scand</source> (<year>1987</year>) <volume>76</volume>:<fpage>523</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0447.1987.tb02913.x</pub-id></citation></ref>
<ref id="B75"><label>75</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hyde</surname> <given-names>TM</given-names></name> <name><surname>Goldberg</surname> <given-names>TE</given-names></name> <name><surname>Egan</surname> <given-names>MF</given-names></name> <name><surname>Lener</surname> <given-names>MC</given-names></name> <name><surname>Weinberger</surname> <given-names>DR</given-names></name></person-group>. <article-title>Frontal release signs and cognition in people with schizophrenia, their siblings and healthy controls</article-title>. <source>Br J Psychiatry</source> (<year>2007</year>) <volume>191</volume>:<fpage>120</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.bp.106.026773</pub-id><pub-id pub-id-type="pmid">17666495</pub-id></citation></ref>
<ref id="B76"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meehl</surname> <given-names>P</given-names></name></person-group>. <article-title>Toward an integrated theory of schizotaxia, schizotypy, and schizophrenia</article-title>. <source>J Pers Disord</source> (<year>1990</year>) <volume>4</volume>:<fpage>1</fpage>&#x02013;<lpage>99</lpage>.<pub-id pub-id-type="doi">10.1521/pedi.1990.4.1.1</pub-id></citation></ref>
<ref id="B77"><label>77</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neelam</surname> <given-names>K</given-names></name> <name><surname>Garg</surname> <given-names>D</given-names></name> <name><surname>Marshall</surname> <given-names>M</given-names></name></person-group>. <article-title>A systematic review and meta-analysis of neurological soft signs in relatives of people with schizophrenia</article-title>. <source>BMC Psychiatry</source> (<year>2011</year>) <volume>11</volume>:<fpage>139</fpage>.<pub-id pub-id-type="doi">10.1186/1471-244X-11-139</pub-id><pub-id pub-id-type="pmid">21859445</pub-id></citation></ref>
<ref id="B78"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arbabi</surname> <given-names>M</given-names></name> <name><surname>Paast</surname> <given-names>N</given-names></name> <name><surname>Karim</surname> <given-names>HR</given-names></name> <name><surname>Fgahfori</surname> <given-names>S</given-names></name> <name><surname>Memari</surname> <given-names>AH</given-names></name></person-group>. <article-title>Mild neurological impairment may indicate a psychomotor endophenotype in patients with borderline personality disorder</article-title>. <source>Psychiatry Res</source> (<year>2016</year>) <volume>245</volume>:<fpage>22</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2016.08.006</pub-id><pub-id pub-id-type="pmid">27526313</pub-id></citation></ref>
<ref id="B79"><label>79</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mrad</surname> <given-names>A</given-names></name> <name><surname>Wassim Krir</surname> <given-names>M</given-names></name> <name><surname>Ajmi</surname> <given-names>I</given-names></name> <name><surname>Gaha</surname> <given-names>L</given-names></name> <name><surname>Mechri</surname> <given-names>A</given-names></name></person-group>. <article-title>Neurological soft signs in euthymic bipolar I patients: a comparative study with healthy siblings and controls</article-title>. <source>Psychiatry Res</source> (<year>2016</year>) <volume>236</volume>:<fpage>173</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2015.11.047</pub-id><pub-id pub-id-type="pmid">26775167</pub-id></citation></ref>
<ref id="B80"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname> <given-names>H</given-names></name> <name><surname>Ozer</surname> <given-names>S</given-names></name> <name><surname>Yagcioglu</surname> <given-names>S</given-names></name></person-group>. <article-title>Neuropsychological, electrophysiological and neurological impairments in patients with obsessive compulsive disorder, their healthy siblings and healthy controls: identifying potential endophenotype(s)</article-title>. <source>Psychiatry Res</source> (<year>2016</year>) <volume>240</volume>:<fpage>110</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="doi">10.1016/j.psychres.2016.04.013</pub-id><pub-id pub-id-type="pmid">27100062</pub-id></citation></ref>
<ref id="B81"><label>81</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lane</surname> <given-names>A</given-names></name> <name><surname>Colgana</surname> <given-names>K</given-names></name> <name><surname>Moynihana</surname> <given-names>F</given-names></name> <name><surname>Burke</surname> <given-names>T</given-names></name> <name><surname>Waddington</surname> <given-names>JH</given-names></name> <name><surname>Larkin</surname> <given-names>D</given-names></name> <etal/></person-group> <article-title>Schizophrenia and neurological soft signs: gender differences in clinical correlates and antecedent factors</article-title>. <source>Psychiatry Res</source> (<year>1996</year>) <volume>64</volume>:<fpage>105</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="doi">10.1016/0165-1781(96)02602-9</pub-id><pub-id pub-id-type="pmid">8912952</pub-id></citation></ref>
<ref id="B82"><label>82</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Bleuler</surname> <given-names>E</given-names></name></person-group>. <source>Dementia praecox oder die Gruppe der Schizophrenien</source>. <publisher-loc>Leipzig, Wien</publisher-loc>: <publisher-name>Franz Deuticke</publisher-name> (<year>1911</year>). p. <fpage>187</fpage>&#x02013;<lpage>200</lpage>.</citation></ref>
<ref id="B83"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malla</surname> <given-names>AK</given-names></name> <name><surname>Norman</surname> <given-names>RM</given-names></name> <name><surname>Aguilar</surname> <given-names>O</given-names></name> <name><surname>Cortese</surname> <given-names>L</given-names></name></person-group>. <article-title>Relationship between neurological &#x02018;&#x02018;soft signs&#x02019;&#x02019; and syndromes of schizophrenia</article-title>. <source>Acta Psychiatr Scand</source> (<year>1997</year>) <volume>96</volume>:<fpage>274</fpage>&#x02013;<lpage>80</lpage>.<pub-id pub-id-type="doi">10.1111/j.1600-0447.1997.tb10163.x</pub-id></citation></ref>
<ref id="B84"><label>84</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peralta</surname> <given-names>V</given-names></name> <name><surname>Moreno-Izco</surname> <given-names>L</given-names></name> <name><surname>Sanchez-Torres</surname> <given-names>A</given-names></name> <name><surname>Garc&#x000ED;a de Jal&#x000F3;n</surname> <given-names>E</given-names></name> <name><surname>Campos</surname> <given-names>MS</given-names></name> <name><surname>Cuesta</surname> <given-names>MJ</given-names></name></person-group>. <article-title>Characterization of the deficit syndrome in drug-naive schizophrenia patients: the role of spontaneous movement disorders and neurological soft signs</article-title>. <source>Schizophr Bull</source> (<year>2014</year>) <volume>40</volume>:<fpage>214</fpage>&#x02013;<lpage>24</lpage>.<pub-id pub-id-type="doi">10.1093/schbul/sbs152</pub-id><pub-id pub-id-type="pmid">23256987</pub-id></citation></ref>
<ref id="B85"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nasrallah</surname> <given-names>HA</given-names></name> <name><surname>McCalley-Whitters</surname> <given-names>M</given-names></name> <name><surname>Kuperman</surname> <given-names>S</given-names></name></person-group>. <article-title>Neurological differences between paranoid and nonparanoid schizophrenia: part I. sensory-motor lateralization</article-title>. <source>J Clin Psychiatry</source> (<year>1982</year>) <volume>43</volume>:<fpage>305</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="pmid">7096270</pub-id></citation></ref>
<ref id="B86"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fish</surname> <given-names>B</given-names></name> <name><surname>Marcus</surname> <given-names>J</given-names></name> <name><surname>Hans</surname> <given-names>SL</given-names></name> <name><surname>Auerbach</surname> <given-names>JG</given-names></name> <name><surname>Perdue</surname> <given-names>S</given-names></name></person-group>. <article-title>Infants at risk for schizophrenia: sequelae of a genetic neurointegrative defect. A review and replication analysis of pandysmaturation in the Jerusalem Infant Development Study</article-title>. <source>Arch Gen Psychiatry</source> (<year>1992</year>) <volume>49</volume>:<fpage>221</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1992.01820030053007</pub-id><pub-id pub-id-type="pmid">1373598</pub-id></citation></ref>
<ref id="B87"><label>87</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johnstone</surname> <given-names>EC</given-names></name> <name><surname>Macmillan</surname> <given-names>JF</given-names></name> <name><surname>Frith</surname> <given-names>CD</given-names></name> <name><surname>Benn</surname> <given-names>DK</given-names></name> <name><surname>Crow</surname> <given-names>TJ</given-names></name></person-group>. <article-title>Further investigation of the predictors of outcome following first schizophrenic episodes</article-title>. <source>Br J Psychiatry</source> (<year>1990</year>) <volume>157</volume>:<fpage>182</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1192/bjp.157.2.182</pub-id><pub-id pub-id-type="pmid">2224368</pub-id></citation></ref>
<ref id="B88"><label>88</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dazzan</surname> <given-names>P</given-names></name> <name><surname>Morgan</surname> <given-names>KD</given-names></name> <name><surname>Orr</surname> <given-names>KG</given-names></name> <name><surname>Hutchinson</surname> <given-names>G</given-names></name> <name><surname>Chitnis</surname> <given-names>X</given-names></name> <name><surname>Suckling</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study</article-title>. <source>Brain</source> (<year>2004</year>) <volume>127</volume>:<fpage>143</fpage>&#x02013;<lpage>53</lpage>.<pub-id pub-id-type="doi">10.1093/brain/awh015</pub-id><pub-id pub-id-type="pmid">14570821</pub-id></citation></ref>
<ref id="B89"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mosher</surname> <given-names>LR</given-names></name> <name><surname>Pollin</surname> <given-names>W</given-names></name> <name><surname>Stabenau</surname> <given-names>JR</given-names></name></person-group>. <article-title>Identical twins discordant for schizophrenia. Neurologic findings</article-title>. <source>Arch Gen Psychiatry</source> (<year>1971</year>) <volume>24</volume>:<fpage>422</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="doi">10.1001/archpsyc.1971.01750110034006</pub-id></citation></ref>
<ref id="B90"><label>90</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friston</surname> <given-names>KJ</given-names></name> <name><surname>Frith</surname> <given-names>CD</given-names></name></person-group>. <article-title>Schizophrenia: a disconnection syndrome?</article-title> <source>Clin Neurosci</source> (<year>1995</year>) <volume>3</volume>:<fpage>89</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">7583624</pub-id></citation></ref>
<ref id="B91"><label>91</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bottmer</surname> <given-names>C</given-names></name> <name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Pantel</surname> <given-names>J</given-names></name> <name><surname>Essig</surname> <given-names>M</given-names></name> <name><surname>Amann</surname> <given-names>M</given-names></name> <name><surname>Schad</surname> <given-names>LR</given-names></name> <etal/></person-group> <article-title>Reduced cerebellar volume and neurological soft signs in first-episode schizophrenia</article-title>. <source>Psychiatry Res</source> (<year>2005</year>) <volume>140</volume>:<fpage>239</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="doi">10.1016/j.pscychresns.2005.02.011</pub-id><pub-id pub-id-type="pmid">16288852</pub-id></citation></ref>
<ref id="B92"><label>92</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thomann</surname> <given-names>PA</given-names></name> <name><surname>W&#x000FC;stenberg</surname> <given-names>T</given-names></name> <name><surname>Santos</surname> <given-names>VD</given-names></name> <name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Essig</surname> <given-names>M</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name></person-group>. <article-title>Neurological soft signs and brain morphology in first-episode schizophrenia</article-title>. <source>Psychol Med</source> (<year>2009</year>) <volume>39</volume>:<fpage>371</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1017/S0033291708003656</pub-id><pub-id pub-id-type="pmid">18578894</pub-id></citation></ref>
<ref id="B93"><label>93</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname> <given-names>NC</given-names></name> <name><surname>Pierson</surname> <given-names>R</given-names></name></person-group>. <article-title>The role of the cerebellum in schizophrenia</article-title>. <source>Biol Psychiatry</source> (<year>2008</year>) <volume>64</volume>:<fpage>81</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="doi">10.1016/j.biopsych.2008.01.003</pub-id></citation></ref>
<ref id="B94"><label>94</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andreasen</surname> <given-names>NC</given-names></name> <name><surname>O&#x02019;Leary</surname> <given-names>DS</given-names></name> <name><surname>Cizadlo</surname> <given-names>T</given-names></name> <name><surname>Arndt</surname> <given-names>S</given-names></name> <name><surname>Rezai</surname> <given-names>K</given-names></name> <name><surname>Ponto</surname> <given-names>LL</given-names></name> <etal/></person-group> <article-title>Schizophrenia and cognitive dysmetria: a positive emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>1996</year>) <volume>93</volume>:<fpage>9985</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.93.18.9985</pub-id></citation></ref>
<ref id="B95"><label>95</label><citation citation-type="other"><person-group person-group-type="author"><name><surname>Kong</surname> <given-names>L</given-names></name> <name><surname>Cui</surname> <given-names>H</given-names></name> <name><surname>Zhang</surname> <given-names>T</given-names></name> <name><surname>Zhu</surname> <given-names>Y</given-names></name> <name><surname>Tang</surname> <given-names>Y</given-names></name> <name><surname>Herold</surname> <given-names>CJ</given-names></name> <etal/></person-group> <article-title>Neurological soft signs related grey matter abnormalities in prodromal psychosis</article-title>. (<year>in press</year>).</citation></ref>
<ref id="B96"><label>96</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname> <given-names>O</given-names></name> <name><surname>Bennett</surname> <given-names>D</given-names></name> <name><surname>Nash</surname> <given-names>T</given-names></name> <name><surname>Arnold</surname> <given-names>S</given-names></name> <name><surname>Brown</surname> <given-names>L</given-names></name> <name><surname>Cai</surname> <given-names>RY</given-names></name> <etal/></person-group> <article-title>Sensory integration deficits support a dimensional view of psychosis and are not limited to schizophrenia</article-title>. <source>Transl Psychiatry</source> (<year>2017</year>) <volume>7</volume>:<fpage>e1118</fpage>.<pub-id pub-id-type="doi">10.1038/tp.2017.69</pub-id><pub-id pub-id-type="pmid">28485725</pub-id></citation></ref>
<ref id="B97"><label>97</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bechter</surname> <given-names>K</given-names></name></person-group>. <article-title>Virus infection as a cause of inflammation in psychiatric disorders</article-title>. <source>Mod Trends Pharmacopsychiatry</source> (<year>2013</year>) <volume>28</volume>:<fpage>49</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="doi">10.1159/000343967</pub-id><pub-id pub-id-type="pmid">25224890</pub-id></citation></ref>
<ref id="B98"><label>98</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname> <given-names>AS</given-names></name></person-group>. <article-title>Epidemiologic studies of exposure to prenatal infection and risk of schizophrenia and autism</article-title>. <source>Dev Neurobiol</source> (<year>2012</year>) <volume>72</volume>:<fpage>1272</fpage>&#x02013;<lpage>6</lpage>.<pub-id pub-id-type="doi">10.1002/dneu.22024</pub-id></citation></ref>
<ref id="B99"><label>99</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>M&#x000FC;ller</surname> <given-names>N</given-names></name></person-group>. <article-title>Immunological aspects of the treatment of depression and schizophrenia</article-title>. <source>Dialogues Clinl Neurosci</source> (<year>2017</year>) <volume>19</volume>:<fpage>55</fpage>&#x02013;<lpage>63</lpage>.</citation></ref>
<ref id="B100"><label>100</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arias</surname> <given-names>I</given-names></name> <name><surname>Sorlozano</surname> <given-names>A</given-names></name> <name><surname>Villegas</surname> <given-names>E</given-names></name> <name><surname>de Dios Luna</surname> <given-names>J</given-names></name> <name><surname>McKenney</surname> <given-names>K</given-names></name> <name><surname>Cervilla</surname> <given-names>J</given-names></name> <etal/></person-group> <article-title>Infectious agents associated with schizophrenia: a meta-analysis</article-title>. <source>Schizophr Res</source> (<year>2012</year>) <volume>136</volume>:<fpage>128</fpage>&#x02013;<lpage>36</lpage>.<pub-id pub-id-type="doi">10.1016/j.schres.2011.10.026</pub-id><pub-id pub-id-type="pmid">22104141</pub-id></citation></ref>
<ref id="B101"><label>101</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khandaker</surname> <given-names>GM</given-names></name> <name><surname>Cousins</surname> <given-names>L</given-names></name> <name><surname>Deakin</surname> <given-names>J</given-names></name> <name><surname>Lennox</surname> <given-names>BR</given-names></name> <name><surname>Yolken</surname> <given-names>R</given-names></name> <name><surname>Jones</surname> <given-names>PB</given-names></name></person-group>. <article-title>Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment</article-title>. <source>Lancet Psychiatry</source> (<year>2015</year>) <volume>2</volume>:<fpage>258</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="doi">10.1016/S2215-0366(14)00122-9</pub-id><pub-id pub-id-type="pmid">26359903</pub-id></citation></ref>
<ref id="B102"><label>102</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sutterland</surname> <given-names>AL</given-names></name> <name><surname>Fond</surname> <given-names>G</given-names></name> <name><surname>Kuin</surname> <given-names>A</given-names></name> <name><surname>Koeter</surname> <given-names>MW</given-names></name> <name><surname>Lutter</surname> <given-names>R</given-names></name> <name><surname>van Gool</surname> <given-names>T</given-names></name> <etal/></person-group> <article-title>Beyond the association. <italic>Toxoplasma gondii</italic> in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis</article-title>. <source>Acta Psychiatr Scand</source> (<year>2015</year>) <volume>132</volume>:<fpage>161</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="doi">10.1111/acps.12423</pub-id></citation></ref>
<ref id="B103"><label>103</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname> <given-names>H</given-names></name> <name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name> <name><surname>McArthur</surname> <given-names>J</given-names></name> <name><surname>Torrey</surname> <given-names>EF</given-names></name> <name><surname>Yolken</surname> <given-names>RH</given-names></name></person-group>. <article-title>Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia</article-title>. <source>Proc Natl Acad Sci U S A</source> (<year>2001</year>) <volume>98</volume>:<fpage>4634</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="doi">10.1073/pnas.061021998</pub-id><pub-id pub-id-type="pmid">11296294</pub-id></citation></ref>
<ref id="B104"><label>104</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname> <given-names>H</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name> <name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Bottmer</surname> <given-names>C</given-names></name> <name><surname>Yolken</surname> <given-names>RH</given-names></name></person-group>. <article-title>HERV-W-related RNA detected in plasma from individuals with recent-onset schizophrenia or schizoaffective disorder</article-title>. <source>Mol Psychiatry</source> (<year>2004</year>) <volume>9</volume>:<fpage>12</fpage>&#x02013;<lpage>3</lpage>.<pub-id pub-id-type="doi">10.1038/sj.mp.4001439</pub-id></citation></ref>
<ref id="B105"><label>105</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname> <given-names>Y</given-names></name> <name><surname>Schr&#x000F6;der</surname> <given-names>J</given-names></name> <name><surname>Nell&#x000E5;ker</surname> <given-names>C</given-names></name> <name><surname>Bottmer</surname> <given-names>C</given-names></name> <name><surname>Bachmann</surname> <given-names>S</given-names></name> <name><surname>Yolken</surname> <given-names>RH</given-names></name> <etal/></person-group> <article-title>Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia</article-title>. <source>Genes Brain Behav</source> (<year>2008</year>) <volume>7</volume>:<fpage>103</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">17559415</pub-id></citation></ref>
<ref id="B106"><label>106</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>F</given-names></name> <name><surname>Karlsson</surname> <given-names>H</given-names></name></person-group>. <article-title>Expression and regulation of human endogenous retrovirus W elements</article-title>. <source>APMIS</source> (<year>2016</year>) <volume>124</volume>:<fpage>52</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="doi">10.1111/apm.12478</pub-id><pub-id pub-id-type="pmid">26818262</pub-id></citation></ref>
<ref id="B107"><label>107</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morrens</surname> <given-names>M</given-names></name> <name><surname>Docx</surname> <given-names>L</given-names></name> <name><surname>Walther</surname> <given-names>S</given-names></name></person-group>. <article-title>Beyond boundaries: in search of an integrative view on motor symptoms in schizophrenia</article-title>. <source>Front Psychiatry</source> (<year>2014</year>) <volume>5</volume>:<fpage>145</fpage>.<pub-id pub-id-type="doi">10.3389/fpsyt.2014.00145</pub-id></citation></ref>
</ref-list>
</back>
</article>